Results 1-524 of 524 (Search time: 0.006 seconds).

Issue DateTitleAuthor(s)SourcescopusWOSFulltext/Archive link
12021Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinomaShao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; ANN-LII CHENG ; Lin Z.-Z.Cells00
22021Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohortChen K.-H.; Lin L.-I.; Yuan C.-T.; Tseng L.-H.; Chao Y.-L.; Liang Y.-H.; Liang J.-T.; Lin B.-R.; ANN-LII CHENG ; Yeh K.-H.British Journal of Cancer00
32021An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular CarcinomaShao Y.-Y.; ANN-LII CHENG ; Hsu C.-H.Oncologist10
42021Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapyHuang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; ANN-LII CHENG ; Hsu C.-H.Journal of Cancer Research and Clinical Oncology00
52021Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaGreten T.F.; Abou-Alfa G.K.; ANN-LII CHENG ; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I.Journal for ImmunoTherapy of Cancer1011
62021Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trialKudo M.; Lim H.Y.; ANN-LII CHENG ; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y.Liver Cancer1010
72021Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophagesOu D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG ; Yang M.-H.; Hsu C.Journal for ImmunoTherapy of Cancer2019
82021Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomasMa W.-L.; Yeh K.-H.; Yao M.; Tang J.-L.; Lin C.-W.; Wang Y.-T.; Yeh Y.-C.; Wang H.-P.; ANN-LII CHENG ; Kuo S.-H.Journal of the Formosan Medical Association22
92021Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinomaChen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG ; Hsu C.; Liang P.-C.; Shih T.T.-F.Diagnostics33
102021High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East AsiaLin C.-H.; Huang R.Y.-J.; Lu T.-P.; Kuo K.-T.; Lo K.-Y.; Chen C.-H.; Chen I.-C.; Lu Y.-S.; Chuang E.Y.; Thiery J.P.; Huang C.-S.; ANN-LII CHENG npj Breast Cancer12
112021Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular CarcinomaHsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG ; Jeng Y.-M.; Hsu C.Liver Cancer1516
122021Pursuing efficacious systemic therapy for hepatocellular carcinomaANN-LII CHENG Nature reviews Gastroenterology and Hepatology67
132021Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpressionRyoo B.-Y.; ANN-LII CHENG ; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S.British Journal of Cancer78
142021Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancerKasper S.; Foch C.; Messinger D.; Esser R.; Lamy F.-X.; Rothe V.; Chen W.; ANN-LII CHENG ; Rouyer M.; Brodowicz T.; Zielinski C.European Journal of Cancer34
152021Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT studyFinn R.S.; Kudo M.; ANN-LII CHENG ; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J.Clinical Cancer Research77
162021Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECTOkusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG ; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H.Journal of Gastroenterology44
172021Evolution of systemic treatment for advanced hepatocellular carcinomaWu T.-C.; Shen Y.-C.; ANN-LII CHENG Kaohsiung Journal of Medical Sciences45
182021Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG ; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M.Cancer68
192021Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patientsChen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; ANN-LII CHENG ; Lu Y.-S.Breast01
202021Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trialGalle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG ; Ducreux M.The Lancet Oncology4440
212021Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-�eB-related signalingKuo S.-H.; Yang S.-H.; Wei M.-F.; Lee H.-W.; Tien Y.-W.; ANN-LII CHENG ; Yeh K.-H.Cancer Cell International11
222021APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapyLau G.; Yu M.-L.; Wong G.; Thompson A.; Ghazinian H.; Hou J.-L.; Piratvisuth T.; Jia J.-D.; Mizokami M.; Cheng G.; Chen G.-F.; Liu Z.-W.; Baatarkhuu O.; ANN-LII CHENG ; Ng W.L.; Lau P.; Mok T.; Chang J.-M.; Hamid S.; Dokmeci A.K.; Gani R.A.; Payawal D.A.; Chow P.; Park J.-W.; Strasser S.I.; Mohamed R.; Win K.M.; Tawesak T.; Sarin S.K.; Omata M.Hepatology International2017
232021Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 StudyQin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG Liver Cancer1916
242020Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaSangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG ; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A.Journal of Hepatology9797
252020Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular CarcinomaKelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG ; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K.Advances in Therapy1618
262020Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patientsYang S.-H.; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; ANN-LII CHENG ; Yeh K.-H.Journal of the Formosan Medical Association22
272020Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular CarcinomaKelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG ; El-Khoueiry A.B.; Abou-Alfa G.K.Clinical Cancer Research2225
282020Milestones in the pathogenesis and management of primary liver cancerNault J.-C.; ANN-LII CHENG ; Sangro B.; Llovet J.M.Journal of Hepatology2525
292020A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumorsLee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C.Investigational New Drugs2624
302020A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese womenTsai M.-S.; Chang S.-H.; Kuo W.-H.; Kuo C.-H.; Li S.-Y.; Wang M.-Y.; Chang D.-Y.; Lu Y.-S.; Huang C.-S.; ANN-LII CHENG ; Lin C.-H.; Chen P.-C.Environment International2221
312020Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialKelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG ; Meyer T.; Abou-Alfa G.K.ESMO open2022
322020IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablationHack S.P.; Spahn J.; Chen M.; ANN-LII CHENG ; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S.Future Oncology4851
332020Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western PopulationsChen C.-H.; Lu Y.-S.; ANN-LII CHENG ; Huang C.-S.; Kuo W.-H.; Wang M.-Y.; Chao M.; Chen I.-C.; Kuo C.-W.; Lu T.-P.; Lin C.-H.Oncologist2024
342020Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infectionTsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; ANN-LII CHENG ; Hsu C.; Taiwan Cooperative Oncology GroupJournal of the Formosan Medical Association66
352020Atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaFinn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG ; IMbrave150 InvestigatorsNew England Journal of Medicine17391721
362020Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinomaANN-LII CHENG ; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M.Journal of Hepatology140147
372020Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III TrialFinn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG ; KEYnote-240 investigatorsJournal of clinical oncology : official journal of the American Society of Clinical Oncology652644
382020Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSOChen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y.Annals of Oncology6665
392020Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survivalChen T.W.-W.; Jan I.-S.; Chang D.-Y.; Lin C.-H.; Chen I.-C.; Chen H.-M.; ANN-LII CHENG ; Lu Y.-S.Journal of Neuro-Oncology108
402020Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study designKelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG ; Rimassa L.Future Oncology3838
412020Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. ReplyFinn R.S.; ANN-LII CHENG The New England journal of medicine15
422020Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumoursde Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG British Journal of Cancer109
432020A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib MonotherapyLin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG ; Lee R.-C.; Chao Y.; Hsu C.Oncologist77
442020A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissueTsai H.-J.; Tai J.J.; Chen L.-T.; Wu M.-S.; Yeh K.-H.; Lin C.-W.; Wang T.-E.; Wang H.-P.; Yu F.-J.; Liou J.-M.; Hsiao C.-F.; Cheng T.-Y.; Yeh H.-J.; Ko C.-W.; Chen M.-J.; Lo G.-H.; Hsu P.-I.; Chang C.-S.; Hwang W.-S.; Chuang S.-S.; Lee H.-W.; Shun C.-T.; Chiu C.-F.; Wang W.-M.; Hsieh C.-Y.; Liu T.-W.; Lin J.-T.; Kuo S.-H.; ANN-LII CHENG Haematologica33
452020Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinomaShen Y.-C.; Hsu C.-L.; Jeng Y.-M.; Ho M.-C.; Ho C.-M.; Yeh C.-P.; Yeh C.-Y.; Hsu M.-C.; Hu R.-H.; ANN-LII CHENG Journal of Hepatology1919
462020A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus StatementsKudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG Liver Cancer7572
472020Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancerYang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; ANN-LII CHENG ; Kuo S.-H.Clinical and Translational Radiation Oncology65
482020Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular CarcinomaAlsina A.; Kudo M.; Vogel A.; ANN-LII CHENG ; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S.Liver Cancer3733
492019The APPLE Association Predident's MessageANN-LII CHENG Liver Cancer0
502019The APPLE association president's messageANN-LII CHENG Liver Cancer0
512019Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinomaHuang T.-C.; Lin C.-C.; Wu Y.-C.; Chia-Hsien Cheng J.; Lee J.-M.; Wang H.-P.; Huang P.-M.; Hsu F.-M.; Yeh K.-H.; ANN-LII CHENG ; Tzen K.-Y.; Hsu C.-H.Journal of the Formosan Medical Association64
522019Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinomaLin Z.-Z.; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; ANN-LII CHENG Liver International1513
532019Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancerPrice T.; Shen L.; Ma B.; Esser R.; Chen W.; Gibbs P.; Lim R.; ANN-LII CHENG Asia-Pacific Journal of Clinical Oncology22
542019Considerations of heterogeneity in clinical trials for hepatocellular carcinomaLiu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG Expert review of Gastroenterology and Hepatology36
552019Novel insights of lymphomagenesis of helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphomaKuo S.-H.; Wu M.-S.; Yeh K.-H.; Lin C.-W.; Hsu P.-N.; Chen L.-T.; ANN-LII CHENG Cancers1819
562019Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib TreatmentLu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; ANN-LII CHENG ; Hsu C.-H.Liver Cancer4037
572019Hypofractionated particle beam therapy for hepatocellular carcinoma-a brief review of clinical effectivenessHsu C.-Y.; Wang C.-W.; ANN-LII CHENG ; Kuo S.-H.World Journal of Gastrointestinal Oncology65
582019Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US PopulationLin C.-H.; Yap Y.S.; Lee K.-H.; Im S.-A.; Naito Y.; Yeo W.; Ueno T.; Kwong A.; Li H.; Huang S.-M.; Leung R.; Han W.; Tan B.; Hu F.-C.; Huang C.-S.; ANN-LII CHENG ; Lu Y.-S.; Asian Breast Cancer Cooperative GroupJournal of the National Cancer Institute4649
592019Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinomaShao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; ANN-LII CHENG ; Hsu C.-H.Liver International2125
602019Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal CancerChen Y.-H.; Wang C.-W.; Wei M.-F.; Tzeng Y.-S.; Lan K.-H.; ANN-LII CHENG ; Kuo S.-H.Cancers88
612019Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular CarcinomaLu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; ANN-LII CHENG Liver Cancer3334
622019CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal CancerChen K.-H.; Lin L.-I.; Tseng L.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; ANN-LII CHENG ; Yeh K.-H.Oncology (Switzerland)33
632019Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid TumorsDoi T.; Yang J.C.-H.; Shitara K.; Naito Y.; ANN-LII CHENG ; Sarashina A.; Pronk L.C.; Takeuchi Y.; Lin C.-C.Targeted Oncology1714
642019Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinomaOu D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; ANN-LII CHENG ; Hsu C.Liver Cancer1414
652019Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinomaEvans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG ; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W.British Journal of Cancer1214
662019Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinomaShao Y.-Y.; Li Y.-S.; Hsu H.-W.; Lin H.; Wang H.-Y.; Wo R.R.; ANN-LII CHENG ; Hsu C.-H.Cancers1111
672019Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG ; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W.British Journal of Cancer22
682018The APPLE Association President's MessageANN-LII CHENG Liver Cancer0
692018Reply to: ��Predictors of sorafenib benefit in patients with hepatocellular carcinoma��Bruix J.; ANN-LII CHENG ; Llovet J.Journal of Hepatology00
702018The APPLE Association President's MessageANN-LII CHENG Liver Cancer0
712018Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancerChen W.-Y.; Wu C.-T.; Wang C.-W.; Lan K.-H.; Liang H.-K.; Huang B.-S.; Chang Y.-L.; Kuo S.-H.; ANN-LII CHENG Radiation Oncology1718
722018Cabozantinib in patients with advanced and progressing hepatocellular carcinomaAbou-Alfa G.K.; Meyer T.; ANN-LII CHENG ; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K.New England Journal of Medicine1039963
732018A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinomaYang S.-H.; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; ANN-LII CHENG ; Yeh K.-H.Anticancer Research32
742018Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infectionYang H.-C.; Tsou H.-H.; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG ; Hsu C.; Taiwan Cooperative Oncology GroupJournal of Hepatology5348
752018Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trialZhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG ; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigatorsThe Lancet Oncology11581143
762018Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in miceTsai C.-L.; Liu W.-L.; Hsu F.-M.; Yang P.-S.; Yen R.-F.; Tzen K.-Y.; ANN-LII CHENG ; Chen P.-J.; Cheng J.C.-H.Hepatology1411
772018Corrigendum to ��Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies�� [J hepatol 67 (2017) 999�V1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))Bruix J.; ANN-LII CHENG ; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J.Journal of Hepatology32
782018Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of ImmunotherapyLin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG ; Hsu C.Seminars in Liver Disease4445
792018Effect of glucocorticoid use on survival in patients with stage I�VIII breast cancerLin C.-H.; Chuang P.-Y.; You S.-L.; Chiang C.-J.; Huang C.-S.; Wang M.-Y.; Chao M.; Lu Y.-S.; ANN-LII CHENG ; Tang C.-H.Breast Cancer Research and Treatment55
802018Adiposity, inflammation, and breast cancer pathogenesis in Asian WomenIyengar N.M.; Chen I.-C.; Zhou X.K.; Giri D.D.; Falcone D.J.; Winston L.A.; Wang H.; Williams S.; Lu Y.-S.; Hsueh T.-H.; ANN-LII CHENG ; Hudis C.A.; Lin C.-H.; Dannenberg A.J.Cancer Prevention Research2926
812018A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular CarcinomaYen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG Liver Cancer1316
822018Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancerChen B.-B.; Lu Y.-S.; Yu C.-W.; Lin C.-H.; Chen T.W.-W.; Wei S.-Y.; ANN-LII CHENG ; Shih T.T.-F.European Radiology78
832018Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinomaChang C.-J.; Yang Y.-H.; Chiu C.-J.; Lu L.-C.; Liao C.-C.; Liang C.-W.; Hsu C.-H.; ANN-LII CHENG International Journal of Cancer3232
842018Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-�eB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cellsWu C.-H.; Yang Y.-H.; Chen M.-R.; Tsai C.-H.; ANN-LII CHENG ; Doong S.-L.PLoS ONE22
852018The HER2 inhibitor lapatinib potentiates doxorubicininduced cardiotoxicity through iNOS signalingHsu W.-T.; Huang C.-Y.; Yen C.Y.T.; ANN-LII CHENG ; Hsieh P.C.H.Theranostics2927
862018A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancerChen T.W.-W.; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG ; Lu Y.-S.; Taiwan Breast Cancer ConsortiumJapanese Journal of Clinical Oncology43
872018Recent developments of c-Met as a therapeutic target in hepatocellular carcinomaBouattour M.; Raymond E.; Qin S.; ANN-LII CHENG ; Stammberger U.; Locatelli G.; Faivre S.Hepatology137140
882018Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialKudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG The Lancet21512139
892018Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of TaiwanLu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG ; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting groupJournal of the Formosan Medical Association6465
902018Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyKudo M.; ANN-LII CHENG ; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y.The Lancet Gastroenterology and Hepatology7975
912017Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphomaYang C.W.-C.; Wang C.-W.; Hong R.-L.; Tsai C.-L.; Yao M.; Tang J.-L.; Lin C.-W.; ANN-LII CHENG ; Kuo S.-H.Journal of Radiation Research68
922017Asia�VPacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateOmata M.; ANN-LII CHENG ; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; Chen P.-J.; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K.Hepatology International995981
932017Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomasMa W.-L.; Yao M.; Liao S.-L.; Tang J.-L.; Wang Y.-C.; Kuo S.-H.; ANN-LII CHENG Oncotarget53
942017Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapyYang S.-H.; Lee J.-C.; Guo J.-C.; Kuo S.-H.; Tien Y.-W.; Kuo T.-C.; ANN-LII CHENG ; Yeh K.-H.PLoS ONE43
952017Corrigendum to ��Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells�� [Neoplasia (United States) 14 (2012) 463�V475](S1476558612801023)(10.1596/neo.12300)Lin Y.-C.; Wu M.-H.; Wei T.-T.; Chuang S.-H.; Chen K.-F.; ANN-LII CHENG ; Chen C.-C.Neoplasia (United States)00
962017Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinomaChen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG ; Shih T.T.-F.European Radiology1416
972017The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)Kuo S.-H.; Tsai H.-J.; Lin C.-W.; Yeh K.-H.; Lee H.-W.; Wei M.-F.; Shun C.-T.; Wu M.-S.; Hsu P.-N.; Chen L.-T.; ANN-LII CHENG Journal of Pathology1010
982017Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cellsShao Y.-Y.; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG Oncotarget88
992017First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphomaKuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG Scientific Reports1415
1002017Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG ; Carrasquilo J.A.Cancer Chemotherapy and Pharmacology1616
1012017Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2011) 55(5) (1041�V1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.Journal of Hepatology11
1022017Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studiesBruix J.; ANN-LII CHENG ; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J.Journal of Hepatology309317
1032017Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to TamoxifenChen I.-C.; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; Lin C.-H.; Wei-Wu Chen T.; ANN-LII CHENG ; Lu Y.-S.Scientific Reports1918
1042017Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric CancerTsai K.-F.; Liou J.-M.; Chen M.-J.; Chen C.-C.; Kuo S.-H.; Lai I.-R.; Yeh K.-H.; Lin M.-T.; Wang H.-P.; ANN-LII CHENG ; Lin J.-T.; Shun C.-T.; Wu M.-S.PLoS ONE2221
1052017Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population studyLu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; ANN-LII CHENG Anticancer Research1314
1062017Tumor compactness improves the preoperative volumetrybased prediction of the pathological complete response of rectal cancer after preoperative concurrent chemoradiotherapyHsu C.-Y.; Wang C.-W.; Kuo C.-C.; Chen Y.-H.; Lan K.-H.; ANN-LII CHENG ; Kuo S.-H.Oncotarget1110
1072017Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC StudyANN-LII CHENG ; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R.Clinical Colorectal Cancer1111
1082017High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinomaShao Y.-Y.; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG ; Hsu C.-H.Japanese Journal of Clinical Oncology2623
1092017Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCLKuo S.-H.; Chen L.-T.; Lin C.-W.; Yeh K.-H.; Shun C.-T.; Tzeng Y.-S.; Liou J.-M.; Wu M.-S.; Hsu P.-N.; ANN-LII CHENG Blood1714
1102017National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patientsShao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; ANN-LII CHENG Oncologist1310
1112017Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database studyLiang Y.-H.; Shao Y.-Y.; Chen H.-M.; ANN-LII CHENG ; Lai M.-S.; Yeh K.-H.Anticancer Research88
1122017Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacyShao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG ; Hsu C.Alimentary Pharmacology and Therapeutics97
1132017Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2017) 66(3) (666�V668) (S0168827816307127) (10.1016/j.jhep.2016.12.007))Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.Journal of Hepatology01
1142017Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialBruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG ; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G.The Lancet19681943
1152017Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancerOkusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG ; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST groupJournal of Cancer Research and Clinical Oncology2116
1162017mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenibMeyer T.; Palmer D.H.; ANN-LII CHENG ; Hocke J.; Loemb? A.-B.; Yen C.-J.Liver International4743
1172017Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyHagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG ; Kihara K.; Sato A.; Tanaka M.ESMO Open841
1182017A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvementChiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; ANN-LII CHENG ; Pu Y.-S.Journal of the Formosan Medical Association76
1192017Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancerLiang Y.-H.; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; ANN-LII CHENG ; Yeh K.-H.Supportive Care in Cancer88
1202016Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerYang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; ANN-LII CHENG ; Kuo S.-H.World Journal of Gastroenterology1921
1212016Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinomaLin H.-H.; Feng W.-C.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG Cancer letters3335
1222016Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapyChen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG ; Shih T.T.-F.Radiology2019
1232016Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaANN-LII CHENG ; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P.Hepatology5760
1242016Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppressionHsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG ; Ou D.-L.Clinical Cancer Research3335
1252016BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancerChen K.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG Medical Oncology1615
1262016A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancerChen B.-B.; Lu Y.-S.; Lin C.-H.; Chen W.-W.; Wu P.-F.; Hsu C.-Y.; Yu C.-W.; Wei S.-Y.; ANN-LII CHENG ; Shih T.T.-F.BMC Cancer1615
1272016A phase i clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment John T KungLiu K.-J.; Chao T.-Y.; Chang J.-Y.; ANN-LII CHENG ; Ch'Ang H.-J.; Kao W.-Y.; Wu Y.-C.; Yu W.-L.; Chung T.-R.; Whang-Peng J.Journal of Biomedical Science1313
1282016Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast CancerChen I.-C.; Chang Y.-C.; Lu Y.-S.; Chung K.-P.; Huang C.-S.; Lu T.-P.; Kuo W.-H.; Wang M.-Y.; Kuo K.-T.; Wu P.-F.; Hsueh T.-H.; Shen C.-Y.; Lin C.-H.; ANN-LII CHENG Scientific Reports1414
1292016Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cellsCho C.-Y.; Huang J.-S.; Shiah S.-G.; Chung S.-Y.; Lay J.-D.; Yang Y.-Y.; Lai G.-M.; ANN-LII CHENG ; Chen L.-T.; Chuang S.-E.RNA2728
1302016Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1�V2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without RadiotherapyLai S.-F.; Chen Y.-H.; Kuo W.-H.; Lien H.-C.; Wang M.-Y.; Lu Y.-S.; Lo C.; Kuo S.-H.; ANN-LII CHENG ; Huang C.-S.Annals of Surgical Oncology2626
1312016Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort studyChen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; ANN-LII CHENG ; Yeh K.-H.BMC Cancer3435
1322016Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancerYang S.-H.; Guo J.-C.; Yeh K.-H.; Tien Y.-W.; ANN-LII CHENG ; Kuo S.-H.Journal of Gastroenterology and Hepatology (Australia)77
1332016Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosisChen I.-C.; Lin C.-H.; Jan I.-S.; ANN-LII CHENG ; Lu Y.-S.Journal of the Formosan Medical Association1411
1342016Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practiceLiang Y.-H.; Shao Y.-Y.; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; ANN-LII CHENG ; Lai M.-S.Journal of Cancer76
1352016Tumor heterogeneity in hepatocellular carcinoma: Facing the challengesLu L.-C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG Liver Cancer7680
1362016Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinomaShao Y.-Y.; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; ANN-LII CHENG Journal of Gastroenterology and Hepatology (Australia)2221
1372016Relapse pattern and treatment outcome of curative radiotherapy for primary cutaneous CD30+ anaplastic large-cell lymphoma: A retrospective cohort studyHuang B.-S.; Chen W.-Y.; Wang C.-W.; ANN-LII CHENG ; Hong J.-H.; Kuo S.-H.Acta Dermato-Venereologica33
1382015The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancerWang Y.-J.; Huang C.-Y.; Hou W.-H.; Wang C.-C.; Lan K.-H.; Chen C.-H.; Yu H.-J.; Lai M.-K.; ANN-LII CHENG ; Liu S.-P.; Pu Y.-S.; Cheng J.C.-H.World Journal of Surgical Oncology44
1392015Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutationsLiang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; ANN-LII CHENG ; Yeh K.-H.Anticancer Research44
1402015Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinomaGuo J.-C.; Huang T.-C.; Lin C.-C.; Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; ANN-LII CHENG ; Hsu C.-H.Journal of Thoracic Oncology1112
1412015Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinomaTsai C.-L.; Hsu F.-M.; Tzen K.-Y.; Liu W.-L.; ANN-LII CHENG ; Cheng J.C.-H.Journal of Gastroenterology and Hepatology (Australia)2425
1422015Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized studyANN-LII CHENG ; Kang Y.-K.; He A.R.; Lim H.Y.; Ryoo B.-Y.; Hung C.-H.; Sheen I.-S.; Izumi N.; Austin T.; Wang Q.; Greenberg J.; Shiratori S.; Beckman R.A.; Kudo M.Journal of Hepatology3035
1432015A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosisWu P.-F.; Lin C.-H.; Kuo C.-H.; Chen W.-W.; Yeh D.-C.; Liao H.-W.; Huang S.-M.; ANN-LII CHENG ; Lu Y.-S.BMC Cancer3631
1442015Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinomaOu D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Hsu C.; ANN-LII CHENG Oncotarget108
1452015Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinomaLiao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; ANN-LII CHENG ; Yang J.C.-H.; Lai M.-S.Clinical Lung Cancer108
1462015Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG World Journal of Gastroenterology3131
1472015AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-B activationTsai H.-J.; Shih N.-Y.; Kuo S.-H.; ANN-LII CHENG ; Lin H.-Y.; Chen T.-Y.; Chang K.-C.; Lin S.-F.; Chang J.S.; Chen L.-T.Leukemia and Lymphoma50
1482015Helicobacter pylori CagA translocation is closely associated with the expression of caga-signaling molecules in low-grade gastric mucosa-associated lymphoid tissue lymphomaKuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Wu M.-S.; Liou J.-M.; Tsai H.-J.; Tzeng Y.-S.; ANN-LII CHENG American Journal of Surgical Pathology1514
1492015Young patients with colorectal cancer have increased risk of second primary cancersLiang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; ANN-LII CHENG ; Yeh K.-H.; Lai M.-S.Japanese Journal of Clinical Oncology109
1502015TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 AssaysLin C.-H.; Chen I.-C.; Huang C.-S.; Hu F.-C.; Kuo W.-H.; Kuo K.-T.; Wang C.-C.; Wu P.-F.; Chang D.-Y.; Wang M.-Y.; Chang C.-H.; Chen W.-W.; Lu Y.-S.; ANN-LII CHENG Scientific Reports910
1512015Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patientsChang T.C.; Shiah H.S.; Yang C.H.; Yeh K.H.; ANN-LII CHENG ; Shen B.N.; Wang Y.W.; Yeh C.G.; Chiang N.J.; Chang J.Y.; Chen L.T.Cancer Chemotherapy and Pharmacology7066
1522015Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpartChang C.; Lin C.-H.; ANN-LII CHENG ; Medeiros L.J.; Chang K.-C.Histopathology1618
1532015Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trialsShao Y.-Y.; Shau W.-Y.; Chan S.-Y.; Lu L.-C.; Hsu C.-H.; ANN-LII CHENG Oncology (Switzerland)2424
1542015High serum transforming growth factor-�]1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenibLin T.-H.; Shao Y.-Y.; Chan S.-Y.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG Clinical Cancer Research6769
1552015Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancerChen Y.-H.; Wei M.-F.; Wang C.-W.; Lee H.-W.; Pan S.-L.; Gao M.; Kuo S.-H.; ANN-LII CHENG ; Teng C.-M.Cancer letters3535
1562015Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in TaiwanShao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; ANN-LII CHENG ; Lai M.-S.Clinical Colorectal Cancer3130
1572015Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapyLu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; ANN-LII CHENG ; Taiwan Breast Cancer ConsortiumClinical Cancer Research5547
1582015The prognostic impact of type 2 diabetes mellitus on early cervical cancer in AsiaKuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; ANN-LII CHENG ; Yang J.C.H.; Lai M.-S.Oncologist1010
1592015High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian countryLin C.-H.; Shen C.-Y.; Lee J.-H.; Huang C.-S.; Yang C.-H.; Kuo W.-H.; Chang D.-Y.; Hsiung C.-N.; Kuo K.-T.; Chen W.-W.; Chen I.-C.; Wu P.-F.; Kuo S.-H.; Chen C.-J.; Lu Y.-S.; ANN-LII CHENG PLoS ONE95
1602015The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseasesChiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Lin Z.-Z.; Lan K.-H.; ANN-LII CHENG ; Kuo S.-H.PLoS ONE99
1612015Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)Hsu C.; Chen B.-B.; Chen C.-H.; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; ANN-LII CHENG Liver Cancer1721
1622015Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cellsTsai Y.-C.; Ho P.-Y.; Tzen K.-Y.; Tuan T.-F.; Liu W.-L.; ANN-LII CHENG ; Pu Y.-S.; Cheng J.C.-H.Molecular Cancer Therapeutics2121
1632014ReplyHsu C.; Chen P.-J.; ANN-LII CHENG Hepatology00
1642014erratum: Oxidative stress enhances AXL-mediated cell migration through AKT1/Rac1-dependent mechanism (Free Radical Biology and Medicine (2013) 65 (1246-1256))Huang J.-S.; Cho C.-Y.; Hong C.-C.; Yan M.-D.; Hsieh M.-C.; Lay J.-D.; Lai G.-M.; ANN-LII CHENG ; Chuang S.-E.Free Radical Biology and Medicine0
1652014Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an east Asian country: A nationwide cancer registry-based studyLin C.-H.; Chuang P.-Y.; Chiang C.-J.; Lu Y.-S.; ANN-LII CHENG ; Kuo W.-H.; Huang C.-S.; Lai M.-S.; You S.-L.; Tang C.-H.Oncologist3032
1662014A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignanciesLin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H.British Journal of Cancer5858
1672014Clinical activity of metronomic chemotherapy in liver cancersShao Y.-Y.; ANN-LII CHENG ; Hsu C.-H.Metronomic Chemotherapy: Pharmacology and Clinical Applications0
1682014Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphomaLiao F.; Hsu Y.-C.; Kuo S.-H.; Yang Y.-C.; Chen J.-P.; Hsu P.-N.; Lin C.-W.; Chen L.-T.; ANN-LII CHENG ; Fann C.S.J.; Lin J.-T.; Wu M.-S.Blood Cancer Journal2217
1692014Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patientsLin Y.-.; Liang Y.-H.; Tsai J.-H.; Liau J.-Y.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG PLoS ONE1616
1702014A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumorsGhamande S.; Lin C.-C.; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; Yang J.C.-H.; ANN-LII CHENG ; Ghalib M.H.; Chuadhary I.; Goel S.Investigational New Drugs1613
1712014Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line-A reply: Despite the same 8-code STR, MA-1 and Pfeiffer are cytogenetically diverseKuo S.-H.; Tsai H.-J.; Weng W.-H.; Li C.-C.; Yeh K.-H.; Chen L.-T.; ANN-LII CHENG Genes Chromosomes and Cancer33
1722014Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancersKao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; ANN-LII CHENG ; Yeh K.-H.Supportive Care in Cancer810
1732014Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapyLu L.-C.; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; ANN-LII CHENG Anticancer Research118
1742014Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunityChen M.-L.; Yan B.-S.; Lu W.-C.; Chen M.-H.; Yu S.-L.; Yang P.-C.; ANN-LII CHENG International Journal of Cancer8887
1752014Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensusANN-LII CHENG ; Li J.; Vaid A.K.; Ma B.B.Y.; Teh C.; Ahn J.B.; Bello M.; Charoentum C.; Chen L.-T.; De Lima Lopes G.; Jr.; Ho G.F.; Kong H.L.; Lam K.O.; Liu T.S.; Park Y.S.; Sriuranpong V.; Sudoyo A.W.; Wang J.-Y.; Zhang J.; Zhang S.Z.; Ciardiello F.; K?hne C.-H.; Shaw M.; Kim T.W.Clinical Colorectal Cancer1615
1762014The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cellsLin Y.-H.; Chen B.Y.-H.; Lai W.-T.; Wu S.-F.; Guh J.-H.; ANN-LII CHENG ; Hsu L.-C.Naunyn-Schmiedeberg's Archives of Pharmacology3230
1772014Helicobacter pylori sensitizes TNF-related apoptosisinducing ligand (TRAIL)-mediated apoptosis in human gastric epithelial cells through regulation of FLIPLin W.-C.; Tsai H.-F.; Liao H.-J.; Tang C.-H.; Wu Y.-Y.; Hsu P.-I.; ANN-LII CHENG ; Hsu P.-N.Cell Death and Disease1716
1782014Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivityKuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; ANN-LII CHENG Blood Cancer Journal3028
1792014Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancerChen K.-H.; Shao Y.-Y.; Lin Z.-Z.; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; ANN-LII CHENG ; Lai M.-S.Oncologist2118
1802014No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifenChen T.W.-W.; Chen H.-M.; Lin C.-H.; Huang C.-S.; ANN-LII CHENG ; Lai M.-S.; Lu Y.-S.Breast Cancer Research and Treatment86
1812014Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behaviorHuang W.-T.; Kuo S.-H.; ANN-LII CHENG ; Lin C.-W.Modern Pathology1413
1822014Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective studyHsu C.; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG Hepatology202189
1832014Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastasesShao Y.-Y.; Ho M.-C.; ANN-LII CHENG ; Hsu C.-H.Journal of the Formosan Medical Association33
1842014Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapyShao Y.-Y.; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; ANN-LII CHENG Journal of Hepatology3942
1852014Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruptionLin Z.-Z.; Chou C.-H.; ANN-LII CHENG ; Liu W.-L.; Chia-Hsien Cheng J.International Journal of Cancer1414
1862014Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert PanelANN-LII CHENG ; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W.Liver International6362
1872014Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapyChen J.L.-Y.; Huang C.-Y.; Huang Y.-S.; Chen R.-J.; Wang C.-W.; Chen Y.-H.; Cheng J.C.-H.; ANN-LII CHENG ; Kuo S.-H.Acta Obstetricia et Gynecologica Scandinavica4650
1882014�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinomaLu L.-C.; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG ; Hsu C.-H.Oncology (Switzerland)1416
1892014Preoperative Prognostic Neurologic Index for Glioblastoma Patients Receiving Tumor ResectionLiang H.-K.; Wang C.-W.; Tseng H.-M.; Huang C.-Y.; Lan K.-H.; Chen Y.-H.; You S.-L.; Cheng J.C.-H.; ANN-LII CHENG ; Kuo S.-H.Annals of Surgical Oncology87
1902014Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinomaOu D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; ANN-LII CHENG Journal of Gastroenterology and Hepatology (Australia)912
1912014Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancerShen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; ANN-LII CHENG Oncology (Switzerland)1312
1922014Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivinOu D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Hsu C.; ANN-LII CHENG Molecular Cancer3630
1932014Recent advances in the prevention of hepatocellular carcinoma recurrenceLu L.-C.; ANN-LII CHENG ; Poon R.T.P.Seminars in Liver Disease4241
1942014Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinomaLiu W.-L.; Gao M.; Tzen K.-Y.; Tsai C.-L.; Hsu F.-M.; ANN-LII CHENG ; Cheng J.C.-H.Oncotarget3334
1952013erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)Hsu C.; Shen Y.-C.; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; Yeh K.-H.Gastric Cancer0
1962013Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cellsYan K.-H.; Lee L.-M.; Hsieh M.-C.; Yan M.-D.; Yao C.-J.; Chang P.-Y.; Chen T.-L.; Chang H.-Y.; ANN-LII CHENG ; Lai G.-M.; Chuang S.-E.Oncology Reports1516
1972013Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinomaTsai Y.-C.; Yeh C.-H.; Tzen K.-Y.; Ho P.-Y.; Tuan T.-F.; Pu Y.-S.; ANN-LII CHENG ; Cheng J.C.-H.European Journal of Cancer2422
1982013Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trialANN-LII CHENG ; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E.Journal of Clinical Oncology542543
1992013The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinomaShao Y.-Y.; Chang Y.-L.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG Oncology (Switzerland)55
2002013Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor PathwayOu D.-L.; Lee B.-S.; Chang Y.-C.; Lin L.-I.; Liou J.-Y.; Hsu C.; ANN-LII CHENG PLoS ONE1011
2012013Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinomaYu H.-C.; Chen H.-J.; Chang Y.-L.; Liu C.-Y.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F.Biochemical Pharmacology4241
2022013Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL studyJohnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG Journal of Clinical Oncology553552
2032013Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of ProteasomeYu H.-C.; Hou D.-R.; Liu C.-Y.; Lin C.-S.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F.PLoS ONE3586
2042013Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor sizeLin Z.-Z.; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; ANN-LII CHENG ; Lai M.-S.PLoS ONE2423
2052013Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinomaShen Y.-C.; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; ANN-LII CHENG British Journal of Cancer138135
2062013Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinomaLu L.-C.; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; ANN-LII CHENG ; Lai M.-S.Cancer99
2072013The aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiformeLee P.-Y.; Chen C.-L.; Lin Z.-Z.; ANN-LII CHENG ; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F.Oncology (Switzerland)119
2082013Randomized phase iii study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: Gest studyUeno H.; Ioka T.; Ikeda M.; Ohkawa S.; Yanagimoto H.; Boku N.; Fukutomi A.; Sugimori K.; Baba H.; Yamao K.; Shimamura T.; Sho M.; Kitano M.; ANN-LII CHENG ; Mizumoto K.; Chen J.-S.; Furuse J.; Funakoshi A.; Hatori T.; Yamaguchi T.; Egawa S.; Sato A.; Ohashi Y.; Okusaka T.; Tanaka M.Journal of Clinical Oncology460433
2092013Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapyChen W.-W.; Lin C.-C.; Huang T.-C.; ANN-LII CHENG ; Yeh K.-H.; Hsu C.-H.Anticancer Research1111
2102013Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: Clinical and biological significanceKuo S.-H.; Chen L.-T.; Lin C.-W.; Wu M.-S.; Hsu P.-N.; Tsai H.-J.; Chu C.-Y.; Tzeng Y.-S.; Wang H.-P.; Yeh K.-H.; ANN-LII CHENG Blood Cancer Journal3634
2112013Helicobacter pylori and mucosa-associated lymphoid tissue: what's newKuo S.-H.; ANN-LII CHENG Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program3938
2122013Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II studyHsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; ANN-LII CHENG Oncology (Switzerland)3940
2132013Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κb is associated with a poor prognosis of pancreatic cancerYang S.-H.; Hsu C.-H.; Lee J.-C.; Tien Y.-W.; Kuo S.-H.; ANN-LII CHENG Oncology (Switzerland)2218
2142013The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclinesChen W.-W.; Chang D.-Y.; Huang S.-M.; Lin C.-H.; Hsu C.; Lin M.-H.; Huang C.-S.; Lu Y.-S.; ANN-LII CHENG Breast45
2152013A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapyShao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG ; Lin Z.-Z.Liver International1213
2162013Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)Park J.-W.; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG Liver International5553
2172013Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3Huang C.-Y.; Lin C.-S.; Tai W.-T.; Hsieh C.-Y.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F.International Journal of Radiation Oncology Biology Physics3436
2182013Clinicopathologic features and responses to radiotherapy of myeloid sarcomaChen W.-Y.; Wang C.-W.; Chang C.-H.; Liu H.-H.; Lan K.-H.; Tang J.-L.; Tien H.-F.; Kuo S.-H.; ANN-LII CHENG Radiation Oncology2224
2192013Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: Complete response to combined intrathecal and systemic rituximabHuang H.-C.; ANN-LII CHENG ; Lin C.-W.; Kuo S.-H.Annals of Hematology54
2202013Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study GroupKim S.J.; Hsu C.; Song Y.-Q.; Tay K.; Hong X.-N.; Cao J.; Kim J.S.; Eom H.S.; Lee J.H.; Zhu J.; Chang K.-M.; Reksodiputro A.H.; Tan D.; Goh Y.T.; Lee J.; Intragumtornchai T.; Chng W.-J.; ANN-LII CHENG ; Lim S.T.; Suh C.; Kwong Y.-L.; Kim W.S.European Journal of Cancer8884
2212013Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisationLin C.-H.; Liu J.M.; Lu Y.-S.; Lan C.; Lee W.-C.; Kuo K.-T.; Wang C.-C.; Chang D.-Y.; Huang C.-S.; ANN-LII CHENG Journal of Clinical Pathology1214
2222013CYP19 genetic polymorphism haplotype aasa is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancerKuo S.-H.; Yang S.-Y.; Lien H.-C.; Lo C.; Lin C.-H.; Lu Y.-S.; ANN-LII CHENG ; Chang K.-J.; Huang C.-S.BioMed Research International99
2232013Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanismHuang J.-S.; Cho C.-Y.; Hong C.-C.; Yan M.-D.; Hsieh M.-C.; Lay J.-D.; Lai G.-M.; ANN-LII CHENG ; Chuang S.-E.Free Radical Biology and Medicine3633
2242013Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cellsTai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; ANN-LII CHENG ; Chen P.-J.; Chen K.-F.Cell Death and Disease145147
2252013Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibodyChen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG British Journal of Pharmacology1412
2262013Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancerLin Y.-L.; Liau J.-Y.; Yu S.-C.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG Translational Oncology810
2272013No evidence of IGH-MALT1-translocation in the Ma-1 cell line-A replyKuo S.-H.; Weng W.-H.; Yeh K.-H.; Chen L.-T.; ANN-LII CHENG Genes Chromosomes and Cancer11
2282013Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomasWu P.-F.; Huang W.-C.; Yang J.C.-H.; Lu Y.-S.; Shih J.-Y.; Wu S.-G.; Lin C.-H.; ANN-LII CHENG Journal of Neuro-Oncology75
2292012Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regressionHsu C.; Shen Y.-C.; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; Yeh K.-H.Gastric Cancer1817
2302012Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinomaShau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; ANN-LII CHENG ; Lai M.-S.Oncologist3132
2312012Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinomaLu Y.-S.; Chou C.-H.; Tzen K.-Y.; Gao M.; ANN-LII CHENG ; Kulp S.K.; Cheng J.C.-H.International Journal of Radiation Oncology Biology Physics2019
2322012Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphomaYang S.-H.; Lin L.-W.; Fang Y.-J.; ANN-LII CHENG ; Kuo S.-H.Annals of Hematology42
2332012CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cellsLin Y.-C.; Chen K.-C.; Chen C.-C.; ANN-LII CHENG ; Chen K.-F.Oral Oncology4947
2342012The emerging epidemic of estrogen-related cancers in young women in a developing Asian countryLin C.-H.; Chen Y.-C.; Chiang C.-J.; Lu Y.-S.; Kuo K.-T.; Huang C.-S.; Cheng W.-F.; Lai M.-S.; You S.-L.; ANN-LII CHENG International Journal of Cancer4139
2352012Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomasKuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Hsu P.-N.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG Blood10687
2362012Expression of BCL10 in cervical cancer has a role in the regulation of cell growth through the activation of NF-κB-dependent cyclin D1 signalingKuo S.-H.; Chou C.-H.; ANN-LII CHENG ; Wang C.-W.; Chen Y.-H.; Chen R.-J.Gynecologic Oncology1817
2372012Medulloblastoma in adults: Treatment outcome, relapse patterns, and prognostic factorsLai S.-F.; Wang C.-W.; Chen Y.-H.; Lan K.-H.; Cheng J.C.-H.; ANN-LII CHENG ; Kuo S.-H.Strahlentherapie und Onkologie1211
2382012Primary squamous cell carcinoma of the thyroid with cardiac metastases and right ventricle outflow tract obstructionChen K.-H.; Chou Y.-H.; ANN-LII CHENG Journal of Clinical Oncology1211
2392012Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapyShao Y.-Y.; Huang C.-C.; Lin S.-D.; Hsu C.-H.; ANN-LII CHENG Clinical Cancer Research3535
2402012Non-bacterial infections in Asian patients treated with alemtuzumab: A retrospective study of the Asian Lymphoma Study GroupKim S.J.; Moon J.H.; Kim H.; Kim J.S.; Hwang Y.Y.; Intragumtornchai T.; Issaragrisil S.; Kwak J.Y.; Lee J.J.; Won J.H.; Reksodiputro A.H.; Lim S.T.; ANN-LII CHENG ; Kim W.S.; Kwong Y.L.Leukemia and Lymphoma2724
2412012Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2AHuang C.-Y.; Wei C.-C.; Chen K.-C.; Chen H.-J.; ANN-LII CHENG ; Chen K.-F.Cancer letters2625
2422012Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trialANN-LII CHENG ; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K.European Journal of Cancer189193
2432012Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancerLu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; ANN-LII CHENG ; Yeh K.-H.Anticancer Research3633
2442012Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinomaYen C.-H.; Lu Y.-C.; Li C.-H.; Lee C.-M.; Chen C.-Y.; Cheng M.-Y.; Huang S.-F.; Chen K.-F.; ANN-LII CHENG ; Liao L.-Y.; Lee Y.-H.W.; Chen Y.-M.A.Molecular Medicine4945
2452012Targeting fibroblast growth factor receptor signaling in hepatocellular carcinomaANN-LII CHENG ; Shen Y.-C.; Zhu A.X.Oncology3538
2462012Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapyKuo Y.-H.; Lin C.-H.; Shau W.-Y.; Chen T.-J.; Yang S.-H.; Huang S.-M.; Hsu C.; Lu Y.-S.; ANN-LII CHENG BMC Cancer1614
2472012Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systemsShao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG British Journal of Cancer2325
2482012A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regressionShen Y.-C.; Hsu C.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG Oncology (Switzerland)3128
2492012Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cellsLin Y.-C.; Wu M.-H.; Wei T.-T.; Chung S.-H.; Chen K.-F.; ANN-LII CHENG ; Chen C.-C.Neoplasia (United States)3334
2502012KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer CellsLin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG PLoS ONE3631
2512012Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG Biochemical Pharmacology3532
2522012Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinomaShao Y.-Y.; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG Oncology2625
2532012BCL10GFP fusion protein as a substrate for analysis of determinants required for Mucosa-Associated Lymphoid Tissue 1 (MALT1)-mediated cleavageJou S.-Y.; Chang C.-C.; Wu C.-H.; Chen M.-R.; Tsai C.-H.; Chuang W.-H.; Chen Y.-H.; ANN-LII CHENG ; Doong S.-L.Journal of Biomedical Science11
2542012The impact of diabetes mellitus on prognosis of early breast cancer in AsiaChen W.-W.; Shao Y.-Y.; Shau W.-Y.; Lin Z.-Z.; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; ANN-LII CHENG ; Lai M.-S.Oncologist3634
2552012Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Liu C.-Y.; Ko C.-H.; Lin M.-W.; Chen P.-J.; Chen K.-F.Molecular Cancer Therapeutics101101
2562012Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinomaShao Y.-Y.; Chen C.-L.; Ho M.-C.; Huang C.-C.; Tu H.-C.; Hsu C.-H.; ANN-LII CHENG Anticancer Research910
2572012Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cellsChen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; Chen P.-J.; ANN-LII CHENG Biochemical Pharmacology4345
2582012Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancerKuo W.-H.; Lin P.-H.; Huang A.-C.; Chien Y.-H.; Liu T.-P.; Lu Y.-S.; Bai L.-Y.; Sargeant A.M.; Lin C.-H.; ANN-LII CHENG ; Hsieh F.-J.; Hwu W.-L.; Chang K.-J.Journal of Human Genetics1818
2592012Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012Ku G.; Tan I.B.; Yau T.; Boku N.; Laohavinij S.; ANN-LII CHENG ; Kang Y.-K.; de Lima Lopes G.The Lancet Oncology5855
2602012Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled studyHsu C.; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; Yu C.-W.; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; ANN-LII CHENG Journal of Hepatology7066
2612011Antiangiogenic strategies for the treatment of hepatocellular carcinomaHsu C.; Shen Y.-C.; ANN-LII CHENG Targeted Therapies for Hepatocellular Carcinoma00
2622011Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001Kuo S.-H.; Hsu C.-H.; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; ANN-LII CHENG European Journal of Cancer1617
2632011Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinomaShao Y.U.-Y.; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; ANN-LII CHENG Anticancer Research12
2642011Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern eraChen I.C.; Lin C.H.; Huang C.S.; Lien H.C.; Hsu C.; Kuo W.H.; Lu Y.S.; ANN-LII CHENG Breast Cancer Research and Treatment6559
2652011Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinomaTai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.Journal of Hepatology138136
2662011A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in TaiwanChen J.-S.; Chao Y.; Hsieh R.-K.; ANN-LII CHENG ; Chen P.-M.; Chiou T.-J.; Chao T.-Y.; Yeh K.-H.; Chen L.-T.; Whang-Peng J.Cancer Chemotherapy and Pharmacology65
2672011Prognostic molecular markers in Women aged 35 years or younger with breast cancer: Is there a difference from the older patients?Lin C.-H.; Lu Y.-S.; Huang C.-S.; Kuo K.-T.; Wang C.-C.; You S.-L.; Lin P.-H.; Chang D.-Y.; Kuo W.-H.; Chang K.-J.; ANN-LII CHENG Journal of Clinical Pathology88
2682011Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2AChen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; Chen P.-J.; ANN-LII CHENG Molecular Cancer Therapeutics3531
2692011Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinibFaivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG ; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E.Clinical Cancer Research6966
2702011Recent advances in the treatment of metastatic colorectal cancer in TaiwanLin Y.-L.; Yeh K.-H.; ANN-LII CHENG Journal of the Formosan Medical Association11
2712011Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of RafChen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; ANN-LII CHENG ; Chen P.-J.; Shiau C.-W.European Journal of Medicinal Chemistry2926
2722011Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapyShao Y.-Y.; Lu L.-C.; ANN-LII CHENG ; Hsu C.-H.Oncologist2926
2732011Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trialsYang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; ANN-LII CHENG Oncology1313
2742011Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinibHarmon C.S.; DePrimo S.E.; Raymond E.; ANN-LII CHENG ; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Lechuga M.J.; Lanzalone S.; Lin X.; Faivre S.Journal of Translational Medicine2120
2752011Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in AsiaHan K.-H.; Kudo M.; Ye S.-L.; Choi J.Y.; Poon R.T.-P.; Seong J.; Park J.-W.; Ichida T.; Chung J.W.; Chow P.; ANN-LII CHENG Oncology9495
2762011Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II studyCh'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG ; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T.International Journal of Radiation Oncology Biology Physics1917
2772011High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapyShao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG Oncology1716
2782011IκB kinases increase Myc protein stability and enhance progression of breast cancer cellsYeh P.-Y.; Lu Y.-S.; Ou D.-L.; ANN-LII CHENG Molecular Cancer2118
2792011Needs for hepatocellular carcinoma control policy in the Asia-Pacific regionBridges J.F.P.; Joy S..; Gallego G.; Kudo M.; Ye S.-L.; Han K.-H.; ANN-LII CHENG ; Blauvelt B.Asian Pacific Journal of Cancer Prevention25
2802011Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cellsChen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; Hsu C.-H.; Chen P.-J.; ANN-LII CHENG Journal of Pharmacology and Experimental Therapeutics242238
2812011Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cellsRodriguez B.A.T.; Weng Y.-I.; Liu T.-M.; Zuo T.; Hsu P.-Y.; Lin C.-H.; ANN-LII CHENG ; Cui H.; Yan P.S.; Huang T.H.-M.Carcinogenesis3934
2822011Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracilHsu C.-Y.; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; ANN-LII CHENG ; Shih T.T.-F.Journal of Hepatology9698
2832011T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvementKuo S.-H.; ANN-LII CHENG ; Lin C.-W.; Hsu C.-H.; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T.Cancer Chemotherapy and Pharmacology127
2842011Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancersHo Y.-F.; Lu W.-C.; Chen R.R.-L.; ANN-LII CHENG ; Yeh K.-H.Anti-Cancer Drugs43
2852011Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter Pylori-independent gastric MALT lymphomaKuo S.-H.; Weng W.-H.; Chen Z.-H.; Hsu P.-N.; Wu M.-S.; Lin C.-W.; Jeng H.-J.; Yeh K.-H.; Tsai H.-J.; Chen L.-T.; ANN-LII CHENG Genes Chromosomes and Cancer79
2862010Liver cancer working group reportKudo M.; Han K.H.; Kokudo N.; ANN-LII CHENG ; Choi B.I.; Furuse J.; Izumi N.; Park J.-W.; Poon R.T.; Sakamoto M.Japanese Journal of Clinical Oncology5252
2872010O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancersWu P.-F.; Kuo K.-T.; Kuo L.-T.; Lin Y.-T.; Lee W.-C.; Lu Y.-S.; Yang C.-H.; Wu R.-M.; Tu Y.-K.; Tasi J.-C.; Tseng H.-M.; Tseng S.-H.; ANN-LII CHENG ; Lin C.-H.Lung Cancer2525
2882010Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinomaShao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG Cancer129137
2892010Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinomaHsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; ANN-LII CHENG British Journal of Cancer110110
2902010Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatinShao Y.-Y.; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; ANN-LII CHENG Japanese Journal of Clinical Oncology2422
2912010Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphomaKuo S.-H.; Yen R.-F.; Lin C.-W.; Chen L.-T.; Tien H.F.; ANN-LII CHENG Annals of Hematology11
2922010Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulationLin P.-H.; Lu Y.-S.; Lin C.-H.; Chang D.-Y.; Huang C.-S.; ANN-LII CHENG ; Yeh K.-H.Anticancer Research54
2932010Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCCLin Z.-Z.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Tsao H.-W.; Lai P.; Lee P.; ANN-LII CHENG ; Hsu H.-C.BMC Cancer8683
2942010Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectivesShen Y.-C.; Hsu C.; ANN-LII CHENG Journal of Gastroenterology5447
2952010Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approachShen Y.-C.; Hsu C.; Chen L.-T.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG Journal of Hepatology113108
2962010The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cellsYan K.-H.; Yao C.-J.; Chang H.-Y.; Lai G.-M.; ANN-LII CHENG ; Chuang S.-E.Molecular Carcinogenesis4237
2972010Clinical Development and Future Direction for the Treatment of Hepatocellular CarcinomaWhang-Peng J.; ANN-LII CHENG ; Hsu C.; Chen C.-M.Journal of Experimental and Clinical Medicine240
2982010Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial designHsu C.; Shen Y.-C.; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG Contemporary Clinical Trials4036
2992010Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cellsWeng Y.-I.; Hsu P.-Y.; Liyanarachchi S.; Liu J.; Deatherage D.E.; Huang Y.-W.; Zuo T.; Rodriguez B.; Lin C.-H.; ANN-LII CHENG ; Huang T.H.-M.Toxicology and Applied Pharmacology9883
3002010Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cellsOu D.-L.; Shen Y.-C.; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; ANN-LII CHENG Cancer Research7067
3012010E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: Possible correlation with stage and treatment responseLiu T.-Y.; Chen S.-U.; Kuo S.-H.; ANN-LII CHENG ; Lin C.-W.Modern Pathology4138
3022010Characteristics and risk factors of oxaliplatin-related hypersensitivity reactionsShao Y.-Y.; Hu F.-C.; Liang J.-T.; Chiu W.-T.; ANN-LII CHENG ; Yang C.-H.Journal of the Formosan Medical Association2522
3032010Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinomaHsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; ANN-LII CHENG Journal of Hepatology109102
3042010Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapyLin C.-H.; Lien H.-C.; Hu F.-C.; Lu Y.-S.; Kuo S.-H.; Wu L.-C.; You S.-L.; ANN-LII CHENG ; Chang K.-J.; Huang C.-S.Journal of Zhejiang University: Science B710
3052010Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivationChen K.-F.; Yu H.-C.; Liu T.-H.; Lee S.-S.; Chen P.-J.; ANN-LII CHENG Journal of Hepatology6665
3062010CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cellsChen K.-F.; Liu C.-Y.; Lin Y.-C.; Yu H.-C.; Liu T.-H.; Hou D.-R.; Chen P.-J.; ANN-LII CHENG Oncogene138130
3072010Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3Chen K.-F.; Tai W.-T.; Liu T.-H.; Huang H.-P.; Lin Y.-C.; Shiau C.-W.; Li P.-K.; Chen P.-J.; ANN-LII CHENG Clinical Cancer Research140136
3082010Translocation of Helicobacter pylori CagA into human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphomaLin W.-C.; Tsai H.-F.; Kuo S.-H.; Wu M.-S.; Lin C.-W.; Hsu P.-I.; ANN-LII CHENG ; Hsu P.-N.Cancer Research7466
3092010Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinomaOmata M.; Lesmana L.A.; Tateishi R.; Chen P.-J.; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; ANN-LII CHENG ; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K.Hepatology International820823
3102010Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphomaChiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; Kuo S.-H.; Hsu C.-H.; Lu Y.-S.; ANN-LII CHENG Cancer letters1919
3112009Lamivudine and hepatitis B reactivationHsu C.; ANN-LII CHENG ; Chen P.-J.Annals of Internal Medicine00
3122009Molecular subtypes of breast cancer emerging in young women in Taiwan: Evidence for more than just westernization as a reason for the disease in AsiaLin C.-H.; Liau J.-Y.; Lu Y.-S.; Huang C.-S.; Lee W.-C.; Kuo K.-T.; Shen Y.-C.; Kuo S.-H.; Lan C.; Liu J.M.; Kuo W.-H.; Chang K.-J.; ANN-LII CHENG Cancer Epidemiology Biomarkers and Prevention9087
3132009Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survivalShen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Hsu C.; ANN-LII CHENG Cancer Epidemiology Biomarkers and Prevention1919
3142009Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatmentShao Y.-Y.; Lin Z.-Z.; Liang P.-C.; Tien Y.-W.; ANN-LII CHENG Anticancer Research11
3152009Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: The molecular mechanism and the clinical applicationLee J.-H.; ANN-LII CHENG ; Lin C.-W.; Kuo S.-H.British Journal of Dermatology129
3162009Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathwayChen K.-F.; Yeh P.-Y.; Hsu C.; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; ANN-LII CHENG Journal of Biological Chemistry8883
3172009EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatmentHuang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; ANN-LII CHENG ; Yang P.-C.Lung Cancer4135
3182009The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinomaLin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; ANN-LII CHENG Journal of Hepatology3839
3192009Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphomaYang S.-H.; Lin Z.-Z.; Kuo S.-H.; ANN-LII CHENG American Journal of Hematology11
3202009Synergistic Effect of Radiation and Interleukin-6 on Hepatitis B Virus Reactivation in Liver Through STAT3 Signaling PathwayChou C.H.; Chen P.-J.; Jeng Y.-M.; ANN-LII CHENG ; Huang L.-R.; Cheng J.C.-H.International Journal of Radiation Oncology Biology Physics2022
3212009Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast - A review of 42 primary and secondary cases in Taiwanese patientsLin Y.-C.; Tsai C.-H.; Wu J.-S.; Huang C.-S.; Kuo S.-H.; Lin C.-W.; ANN-LII CHENG Leukemia and Lymphoma2620
3222009Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialANN-LII CHENG ; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z.The Lancet Oncology42544079
3232009Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapyHsu C.; Wei S.-C.; ANN-LII CHENG ; Chen P.-J.Hepatology43
3242009National Center of Excellence for Clinical Trials and Research at National Taiwan University HospitalLin C.-C.; Yang C.-H.; ANN-LII CHENG ; Chan W.-K.; Ho N.-N.Drug Information Journal32
3252009Sorafenib for the treatment of hepatocellular carcinoma across geographic regionsHsu C.; Shen Y.-C.; ANN-LII CHENG Expert review of Clinical Pharmacology70
3262009Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method - Analysis of 2010 Taiwanese patientsChen C.-H.; Hu F.-C.; Huang G.-T.; Lee P.-H.; Tsang Y.-M.; ANN-LII CHENG ; Chen D.-S.; Wang J.-D.; Sheu J.-C.European Journal of Cancer6562
3272009Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancerCh'ang H.-J.; Huang C.-L.; Wang H.-P.; Shiah H.-S.; Chang M.-C.; Jan C.-M.; Chen J.-S.; Tien Y.-W.; Hwang T.-L.; Lin J.-T.; ANN-LII CHENG ; Whang-Peng J.; Chen L.-T.Cancer Chemotherapy and Pharmacology1011
3282009Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder CancerLin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; ANN-LII CHENG ; Pu Y.-S.International Journal of Radiation Oncology Biology Physics2318
3292009Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II studyFaivre S.; Raymond E.; Boucher E.; Douillard J.; Lim H.Y.; Kim J.S.; Zappa M.; Lanzalone S.; Lin X.; DePrimo S.; Harmon C.; Ruiz-Garcia A.; Lechuga M.J.; ANN-LII CHENG The Lancet Oncology249230
3302009Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinomaOu D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; ANN-LII CHENG Clinical Cancer Research2831
3312008Organization-based performance measures of cancer care quality: Core measure development for breast cancer in TaiwanChung K.-P.; Lai M.-S.; Cheng S.H.; Tang S.-T.; Huang C.C.; ANN-LII CHENG ; Hsieh P.-C.European Journal of Cancer Care2424
3322008Sorafenib benefits Asian patients with advanced HCCANN-LII CHENG Oncology Report
3332008Prognostic factors in extrapulmonary small cell carcinomas: A large retrospective studyLin Y.-L.; Chung C.-Y.; Chang C.-S.; Wu J.-S.; Kuo K.-T.; Kuo S.-H.; ANN-LII CHENG Oncology1916
3342008FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C δ signalingHung J.-H.; Lu Y.-S.; Wang Y.-C.; Ma Y.-H.; Wang D.-S.; Kulp S.K.; Muthusamy N.; Byrd J.C.; ANN-LII CHENG ; Chen C.-S.Cancer Research9491
3352008Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinomaLin C.-C.; Pu Y.-S.; Hsu C.-H.; Keng H.-Y.; ANN-LII CHENG ; Yang C.-H.Urologic Oncology: Seminars and Original Investigations87
3362008Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: Need for a revisit of surgical treatmentKuo S.-H.; Chen L.-T.; Wu M.-S.; Lin C.-W.; Yeh K.-H.; Kuo K.-T.; Yeh P.-Y.; Tzeng Y.-S.; Wang H.-P.; Hsu P.-N.; Lin J.-T.; ANN-LII CHENG Annals of Surgery1413
3372008Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulationHuang T.-C.; Yeh K.-H.; ANN-LII CHENG ; Hsu C.-H.Anticancer Research138
3382008OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinomaGao M.; Yeh P.Y.; Lu Y.-S.; Hsu C.-H.; Chen K.-F.; Lee W.-C.; Feng W.-C.; Chen C.-S.; Kuo M.-L.; ANN-LII CHENG Cancer Research127121
3392008Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trialHsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG ; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H.Lung Cancer1311
3402008A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trialHsu C.; Hsiung C.A.; Su I.-J.; Hwang W.-S.; Wang M.-C.; Lin S.-F.; Lin T.-H.; Hsiao H.-H.; Young J.-H.; Chang M.-C.; Liao Y.-M.; Li C.-C.; Wu H.-B.; Tien H.-F.; Chao T.-Y.; Liu T.-W.; ANN-LII CHENG ; Chen P.-J.Hepatology262238
3412008Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatmentLin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; ANN-LII CHENG ; Yang P.-C.; Yang C.-H.Lung Cancer41
3422008NF-κB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cellsGao M.; Yeh P.Y.; Lu Y.-S.; Chang W.C.; Kuo M.-L.; ANN-LII CHENG Biochemical and Biophysical Research Communications2017
3432008Comprehensive Locoregional Treatment and Systemic Therapy for Postmastectomy Isolated Locoregional RecurrenceKuo S.-H.; Huang C.-S.; Kuo W.-H.; ANN-LII CHENG ; Chang K.-J.; Chia-Hsien Cheng J.International Journal of Radiation Oncology Biology Physics3327
3442008Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathwayDai H.-Y.; Hong C.-C.; Liang S.-C.; Yan M.-D.; Lai G.-M.; ANN-LII CHENG ; Chuang S.-E.Molecular Carcinogenesis3534
3452008Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemiaHong C.-C.; Lay J.-D.; Huang J.-S.; ANN-LII CHENG ; Tang J.-L.; Lin M.-T.; Lai G.-M.; Chuang S.-E.Cancer letters161155
3462008Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cellsChen K.-F.; Yeh P.-Y.; Yeh K.-H.; Lu Y.-S.; Huang S.-Y.; ANN-LII CHENG Cancer Research110102
3472008Differential expression of glucocorticoid receptor in carcinomas of the human digestive systemLien H.-C.; Lu Y.-S.; Shun C.-T.; Yao Y.-T.; Chang W.-C.; ANN-LII CHENG Histopathology1716
3482008Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapyYang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; ANN-LII CHENG ; Pao W.; Yang P.-C.Journal of Clinical Oncology233220
3492008Overexpression of B cell activating factor of TNF family (BAFF) is associated with Helicobacter pylori independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphomaKuo S.-H.; Yeh P.-Y.; Chen L.-T.; Wu M.-S.; Lin C.-W.; Yeh K.-H.; Tzeng Y.-S.; Chen J.-Y.; Hsu P.-N.; Lin J.-T.; ANN-LII CHENG Blood4545
3502008Disseminated peritoneal leiomyomatosis responds to systemic chemotherapyLin Y.-C.; Wei L.-H.; Shun C.-T.; ANN-LII CHENG ; Hsu C.-H.Oncology2720
3512008Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cellsLin H.-J.L.; Zuo T.; Lin C.-H.; Chieh T.K.; Liyanarachchi S.; Sun S.; Shen R.; Deatherage D.E.; Potter D.; Asamoto L.; Lin S.; Yan P.S.; ANN-LII CHENG ; Ostrowski M.C.; Huang T.H.-M.Cancer Research5855
3522007Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancerLin C.-C.; Hsu C.-H.; Cheng J.C.; Wang H.-P.; Lee J.-M.; Yeh K.-H.; Yang C.-H.; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C.Annals of Oncology3836
3532007Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trialLin C.-C.; Hsu C.-H.; Hour T.-C.; ANN-LII CHENG ; Huang C.-Y.; Huang K.-H.; Chen J.; Pu Y.-S.Urologic Oncology: Seminars and Original Investigations55
3542007Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXLLay J.-D.; Hong C.-C.; Huang J.-S.; Yang Y.-Y.; Pao C.-Y.; Liu C.-H.; Lai Y.-P.; Lai G.-M.; ANN-LII CHENG ; Su I.-J.; Chuang S.-E.Cancer Research8478
3552007Epidemiology of multiple myeloma in Taiwan: Increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 yearsHuang S.-Y.; Yao M.; Tang J.-L.; Lee W.-C.; Tsay W.; ANN-LII CHENG ; Wang C.-H.; Chen Y.-C.; Shen M.-C.; Tien H.-F.Cancer7468
3562007Molecular targeted therapy for advanced hepatocellular carcinomaShen Y.C.; Hsu C.; ANN-LII CHENG Targeted Oncology64
3572007Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach - Significance of tumour cell clonality and BCL10 expressionKuo S.-H.; Chen L.-T.; Wu M.-S.; Kuo K.-T.; Yeh K.-H.; Doong S.-L.; Yeh P.-Y.; Hsu H.-C.; Tzeng Y.-S.; Lin C.-W.; Lin J.-T.; ANN-LII CHENG Journal of Pathology1811
3582007Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinomaLin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; ANN-LII CHENG ; Hsu C.-H.Anti-Cancer Drugs108
3592007Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinomaLu Y.-S.; Kashida Y.; Kulp S.K.; Wang Y.-C.; Wang D.; Hung J.-H.; Tang M.; Lin Z.-Z.; Chen T.-J.; ANN-LII CHENG ; Chen C.-S.Hepatology7678
3602007A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinomaChen Y.-M.; Yu C.-J.; Yang C.-H.; Perng R.-P.; Tsai C.-M.; Shih J.-F.; ANN-LII CHENG ; Lefresne F.; Barbier M.; Pouget J.-C.; Yang P.-C.Lung Cancer1412
3612007Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based RegimensLin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG ; Pu Y.-S.Urology2018
3622007Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trialLin C.-C.; Hsu C.; Hsu C.-H.; Hsu W.-L.; ANN-LII CHENG ; Yang C.-H.Investigational New Drugs9796
3632007Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial CarcinomaLin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG ; Vogelzang N.J.; Pu Y.-S.Journal of Urology2018
3642007Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cellsChia H.C.; Chen P.-J.; Lee P.-H.; ANN-LII CHENG ; Hsu H.-C.; Cheng J.C.-H.Clinical Cancer Research8075
3652007Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II studyLin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG ; Pu Y.-S.Anti-Cancer Drugs3128
3662007Clinical studies with curcuminHsu C.-H.; ANN-LII CHENG Advances in Experimental Medicine and Biology324289
3672007A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancerLin C.-C.; ANN-LII CHENG ; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H.Anticancer Research22
3682006Primary thyroid lymphoma mimicking subacute thyroiditis [4]Yang Y.-S.; Wu M.-Z.; ANN-LII CHENG ; Chang T.-C.Acta Cytologica9
3692006A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleusPei Y.Y.; Kuo S.-H.; Yeh K.-H.; Chuang S.-E.; Hsu C.-H.; Wen C.C.; Lin H.-I.; Gao M.; ANN-LII CHENG Journal of Biological Chemistry4238
3702006Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphomaCheng T.-Y.; Lin J.-T.; Chen L.-T.; Shun C.-T.; Wang H.-P.; Lin M.-T.; Wang T.-E.; ANN-LII CHENG ; Wu M.-S.Journal of Clinical Oncology8170
3712006Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivityLu Y.-S.; Lien H.-C.; Yeh P.-Y.; Kuo S.-H.; Chang W.-C.; Kuo M.-L.; ANN-LII CHENG Lung Cancer3029
3722006Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazoneYao C.-J.; Lai G.-M.; Chan C.-F.; ANN-LII CHENG ; Yang Y.-Y.; Chuang S.-E.International Journal of Cancer6565
3732006An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancerChao Y.; Li C.P.; Chao T.Y.; Su W.C.; Hsieh R.K.; Wu M.F.; Yeh K.H.; Kao W.Y.; Chen L.T.; ANN-LII CHENG British Journal of Cancer1313
3742006Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancerCh'ang H.-J.; Wang C.-C.; ANN-LII CHENG ; Hsu C.; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T.Journal of Gastroenterology and Hepatology (Australia)77
3752006Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicityLin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG ; Chen J.; Vogelzang N.J.; Pu Y.-S.Cancer2324
3762006Differential expression of glucocorticoid receptor in human breast tissues and related neoplasmsLien H.-C.; Lu Y.-S.; ANN-LII CHENG ; Chang W.-C.; Jeng Y.-M.; Kuo Y.-H.; Huang C.-S.; Chang K.-J.; Yao Y.-T.Journal of Pathology4646
3772006Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancerShiah H.-S.; ANN-LII CHENG ; Hsu C.; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T.Journal of Gastroenterology and Hepatology (Australia)65
3782006Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: Implication from age-period-cohort analysisHsu C.; Shen Y.-C.; Cheng C.-C.; Hong R.-L.; Chang C.-J.; ANN-LII CHENG Cancer Epidemiology Biomarkers and Prevention6149
3792006Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-κB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHaLu Y.-S.; Yeh P.-Y.; Chuang S.-E.; Gao M.; Kuo M.-L.; ANN-LII CHENG Journal of Endocrinology2220
3802006Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal originLin C.-H.; Kuo K.-T.; Chuang S.-S.; Kuo S.-H.; Chang J.H.; Chang K.-C.; Hsu H.-C.; Tien H.-F.; ANN-LII CHENG Clinical Cancer Research10390
3812005Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: Tissue accumulation and the reversibility after washout are tissue-selectiveLin C.-J.; Wu M.-H.; Hsueh Y.-M.; Sun S.S.-M.; ANN-LII CHENG Cancer Chemotherapy and Pharmacology2218
3822005Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lungYeh K.-H.; Yeh S.-H.; Wan J.-P.; Shen Y.-C.; ANN-LII CHENG Anti-Cancer Drugs43
3832005Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trialsKuo S.-H.; Yang C.-H.; Yu C.-J.; Hsu C.; ANN-LII CHENG ; Yang P.-C.Lung Cancer77
3842005Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatmentYang C.-H.; Chen M.-C.; ANN-LII CHENG ; Hsu C.-H.; Yeh K.-H.; Yu Y.-C.; Whang-Peng J.; Yang P.-C.Oncology54
3852005Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptorsLu Y.-S.; Lien H.-C.; Yeh P.-Y.; Yeh K.-H.; Kuo M.-L.; Kuo S.-H.; ANN-LII CHENG World Journal of Gastroenterology2524
3862005Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications from age-period-cohort analysisShen Y.-C.; Chang C.-J.; Hsu C.; Cheng C.-C.; Chiu C.-F.; ANN-LII CHENG Cancer Epidemiology Biomarkers and Prevention118107
3872005Identification and characterization of a novel gene Saf transcribed from the opposite strand of FasYan M.-D.; Hong C.-C.; Lai G.-M.; ANN-LII CHENG ; Lin Y.-W.; Chuang S.-E.Human Molecular Genetics7975
3882005Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factorsHsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Hsieh F.-J.; ANN-LII CHENG Radiology2322
3892005Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitroHsu C.-H.; Gao M.; Chen C.-L.; Yeh P.-Y.; ANN-LII CHENG Oncology3937
3902005Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patientsSu W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG ; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J.World Journal of Gastroenterology1814
3912005Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family proteinYang C.-H.; Huang C.-J.; Yang C.-S.; Chu Y.-C.; ANN-LII CHENG ; Whang-Peng J.; Yang P.-C.Cancer Research9286
3922005Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphomaChen L.-T.; Lin J.-T.; Tai J.J.; Chen G.-H.; Yeh H.-Z.; Yang S.-S.; Wang H.-P.; Kuo S.-H.; Sheu B.-S.; Jan C.-M.; Wang W.-M.; Wang T.-E.; Wu C.-W.; Chen C.-L.; Su I.-J.; Whang-Peng J.; ANN-LII CHENG Journal of the National Cancer Institute164131
3932005Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21 )Yeh K.-H.; Kuo S.-H.; Chen L.-T.; Mao T.-L.; Doong S.-L.; Wu M.-S.; Hsu H.-C.; Tzeng Y.-S.; Chen C.-L.; Lin J.-T.; ANN-LII CHENG Blood6655
3942005Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancerYeh K.H.; Lu Y.S.; Hsu C.H.; Lin J.F.; Chao H.J.; Huang T.C.; Chung C.Y.; Chang C.S.; Yang C.H.; ANN-LII CHENG British Journal of Cancer77
3952005Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancerYeh K.-H.; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; ANN-LII CHENG Oncology2121
3962005Expression of CD86 and increased inflitration of NK cells are associated with Helicobacter pylori-dependent state of early stage high-grade gastric MALT lymphomaKuo S.-H.; Chen L.-T.; Chen C.-L.; Doong S.-L.; Yeh K.-H.; Wu M.-S.; Mao T.-L.; Hsu H.-C.; Wang H.-P.; Lin J.-T.; ANN-LII CHENG World Journal of Gastroenterology1414
3972004Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinomaLu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; ANN-LII CHENG Hepato-Gastroenterology1413
3982004Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancerChao Y.; Yeh K.H.; Chang C.J.; Chen L.T.; Chao T.Y.; Wu M.F.; Chang C.S.; Chang J.Y.; Chung C.Y.; Kao W.Y.; Hsieh R.K.; ANN-LII CHENG British Journal of Cancer7162
3992004Recent advances in therapy for gastric cancerYeh K.-H.; ANN-LII CHENG Journal of the Formosan Medical Association77
4002004Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapyHsu C.-H.; Hsu H.-C.; Chen H.-L.; Gao M.; Yeh P.-Y.; Chen P.-J.; ANN-LII CHENG Anticancer Research4741
4012004Recent advances in non-surgical treatment for advanced hepatocellular carcinomaHsu C.; Cheng J.C.-H.; ANN-LII CHENG Journal of the Formosan Medical Association2318
4022004Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell deathYeh P.Y.; Chuang S.-E.; Yeh K.-H.; Song Y.C.; Chang L.L.-Y.; ANN-LII CHENG Oncogene6464
4032004Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA PeptidesLiu K.-J.; Wang C.-C.; Chen L.-T.; ANN-LII CHENG ; Lin D.-T.; Wu Y.-C.; Yu W.-L.; Hung Y.-M.; Yang H.-Y.; Juang S.-H.; Whang-Peng J.Clinical Cancer Research7874
4042004Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cellsYeh K.-H.; ANN-LII CHENG ; Wan J.-P.; Lin C.-S.; Liu C.-C.Anti-Cancer Drugs3733
4052004Promoter polymorphisms of tumor necrosis factor-α are associated with risk of gastric mucosa-associated lymphoid tissue lymphomaWu M.-S.; Chen L.-T.; Shun C.-T.; Huang S.-P.; Chiu H.-M.; Wang H.-P.; Lin M.-T.; ANN-LII CHENG ; Lin J.-T.International Journal of Cancer6054
4062004Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomasKuo S.-H.; Chen L.-T.; Yeh K.-H.; Wu M.-S.; Hsu H.-C.; Yeh P.-Y.; Mao T.-L.; Chen C.-L.; Doong S.-L.; Lin J.-T.; ANN-LII CHENG Journal of Clinical Oncology6353
4072004Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cellsPu Y.-S.; Hour T.-C.; Chuang S.-E.; ANN-LII CHENG ; Lai M.-K.; Kuo M.-L.Prostate6970
4082004Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-κB activation by protein phosphatase 4-mediated NF-κB p 65 Thr dephosphorylationYeh P.Y.; Yeh K.-H.; Chuang S.-E.; Song Y.C.; ANN-LII CHENG Journal of Biological Chemistry9187
4092004Effect of interleukin-1β and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphomaWu M.-S.; Shun C.-T.; Huang S.-P.; ANN-LII CHENG ; Chen L.-T.; Lin J.-T.Haematologica1816
4102004Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell linesShen Y.-C.; Hsu C.; Chen J.-Y.; ANN-LII CHENG British Journal of Cancer45
4112004Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tractHsu C.; Shen Y.-C.; Yang C.-H.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG British Journal of Cancer4240
4122003Survival-weighted health profile for long-term survivors of acute myelogenous leukemiaHsu C.; Wang J.-D.; Hwang J.-S.; Tien H.-F.; Chang S.-M.; ANN-LII CHENG ; Chen Y.-C.; Tang J.-L.Quality of Life Research2623
4132003Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of ageLiang J.T.; Huang K.C.; ANN-LII CHENG ; Jeng Y.M.; Wu M.S.; Wang S.M.British Journal of Surgery138124
4142003Involvement of nuclear transcription factor-κB in low-dose doxorubicin-induced drug resistance of cervical carcinoma cellsYeh P.Y.; Chuang S.-E.; Yeh K.-H.; Song Y.C.; ANN-LII CHENG Biochemical Pharmacology3631
4152003Hepatitis B virus X protein activates a survival signaling by linking Src to phosphatidylinositol 3-kinaseShih W.-L.; Kuo M.-L.; Chuang S.-E.; ANN-LII CHENG ; Doong S.-L.Journal of Biological Chemistry5249
4162003Low-dose thalidomide treatment for advanced hepatocellular carcinomaHsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Yang P.-M.; Lai M.-Y.; Lee P.-H.; ANN-LII CHENG Oncology8777
4172003Direct cardiac effects of As2O3 in rabbits: Evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administrationWu M.-H.; Lin C.-J.; Chen C.-L.; Su M.-J.; Sun S.S.-M.; ANN-LII CHENG Toxicology and Applied Pharmacology2623
4182003Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphomaANN-LII CHENG ; Hsiung C.A.; Su I.-J.; Chen P.-J.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.Hepatology249222
4192003High-dose Tamoxifen Modulates Drug Resistance to Doxorubicin, Dacarbazine and Ifosfamide in Metastatic Uterine LeiomyosarcomaYeh K.-H.; Lu Y.-S.; Hsiao C.-H.; ANN-LII CHENG Anticancer Research33
4202002High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resectionLiang J.-T.; Huang K.-C.; Lai H.-S.; Lee P.-H.; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG ; Hsu C.-H.; Yeh K.-H.; Wang S.-M.; Tang C.; Chang K.-J.International Journal of Cancer10797
4212002Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapyKuo S.-H.; Lin L.-I.; Chang C.-J.; Liu Y.-R.; Lin K.-S.; ANN-LII CHENG Journal of Clinical Microbiology2020
4222002Pre-clinical and early-phase clinical studies of curcumin as chemopreventive agent for endemic cancers in Taiwan.Hsu C.H.; Chuang S.E.; Hergenhahn M.; Kuo M.L.; Lin J.K.; Hsieh C.Y.; ANN-LII CHENG Gan to kagaku ryoho. Cancer & chemotherapy130
4232002Prognostic value of multidrug resistance 1, glutathione-S-transferase-π and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapyHsu C.-H.; Chen C.-L.; Hong R.-L.; Chen K.-L.; Lin J.-F.; ANN-LII CHENG Oncology3024
4242002Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatinHsu C.-H.; Hergenhahn M.; Chuang S.-E.; Yeh P.-Y.; Wu T.-C.; Gao M.; ANN-LII CHENG Anticancer Research1412
4252002A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracilHsu C.-H.; ANN-LII CHENG ; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H.Anticancer Research1212
4262002Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancerYang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; ANN-LII CHENG ; Liu M.Y.; Chiang S.C.; Chen Y.M.; Luh K.T.; Huang M.H.; Yang P.-C.; Perng R.-P.British Journal of Cancer2420
4272002The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cellsHergenhahn M.; Soto U.; Weninger A.; Polack A.; Hsu C.-H.; ANN-LII CHENG ; R?sl F.Molecular Carcinogenesis6159
4282002Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activationYeh P.Y.; Chuang S.-E.; Yeh K.-H.; Song Y.C.; Ea C.-K.; ANN-LII CHENG Biochemical Pharmacology128125
4292002Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinomaHsu C.; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; Chang K.-J.; ANN-LII CHENG Cancer1110
4302002HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivityHsu C.; Huang C.-L.; Hsu H.-C.; Lee P.-H.; Wang S.-J.; ANN-LII CHENG Cancer3731
4312002P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resectionLiang J.-T.; Huang K.-C.; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG ; Hsu C.-H.; Yeh K.-H.; Wang S.-M.; Chang K.-J.International Journal of Cancer6354
4322002Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphomaHuang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; ANN-LII CHENG Leukemia and Lymphoma95
4332002Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cellsChuang S.-E.; Yeh P.-Y.; Lu Y.-S.; Lai G.-M.; Liao C.-M.; Gao M.; ANN-LII CHENG Biochemical Pharmacology152135
4342001Prospective study of Helicobacter pylori eradication therapy in stage IE high-grade mucosa-associated lymphoid tissue lymphoma of the stomachChen L.-T.; Lin J.-T.; Shyu R.-Y.; Jan C.-M.; Chen C.-L.; Chiang I.-P.; Liu S.-M.; Su I.-J.; ANN-LII CHENG Journal of Clinical Oncology9576
4352001Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: Does histologic evidence of MALT affect chemotherapy response?Hsu C.; Chen C.-L.; Chen L.-T.; Liu H.-T.; Chen Y.-C.; Jan C.-M.; Liu C.-S.; ANN-LII CHENG Cancer13
4362001A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancerLin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; ANN-LII CHENG ; Pu Y.-S.Anticancer Research1413
4372001Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinomaHsu C.-H.; Chen J.; Wu C.-Y.; ANN-LII CHENG ; Pu Y.-S.Anticancer Research2724
4382001Nuclear extracellular signal-regulated kinase 2 phosphorylates p53 at Thr55 in response to doxorubicinYeh P.Y.; Chuang S.-E.; Yeh K.-H.; Chyi Song Y.; ANN-LII CHENG Biochemical and Biophysical Research Communications3234
4392000Hepatitis b virus x protein inhibits transforming growth factor-β-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathwayShih W.-L.; Kuo M.-L.; Chuang S.-E.; ANN-LII CHENG ; Doong S.-L.Journal of Biological Chemistry173163
4402000Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functionsWang K.-C.; ANN-LII CHENG ; Chuang S.-E.; Hsu H.-C.; Su I.-J.Experimental Hematology2422
4412000Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomachLiu H.-T.; Hsu C.; Chen C.-L.; Chiang I.-P.; Chen L.-T.; Chen Y.-C.; ANN-LII CHENG American Journal of Hematology33
4422000Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesisChuang S.E.; Kuo M.L.; Hsu C.H.; Chen C.R.; Lin J.K.; Lai G.M.; Hsieh C.Y.; ANN-LII CHENG Carcinogenesis229201
4432000Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: Direct evidence from colony forming unit- granulocyte and monocyte (CFU-GM) clonogenic assayYeh K.-H.; Yeh S.-H.; Chang Y.-S.; ANN-LII CHENG Pharmacology and Toxicology1512
4442000Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in ratsChuang S.-E.; ANN-LII CHENG ; Lin J.-K.; Kuo M.-L.Food and Chemical Toxicology167139
4452000Metaplastic carcinoma of the breast-analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancerKuo S.-H.; Chen C.-L.; Huang C.-S.; ANN-LII CHENG Anticancer Research2825
4462000Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracilYeh K.-H.; Yeh S.-H.; Hsu C.-H.; Wang T.-M.; Ma I.-F.; ANN-LII CHENG British Journal of Cancer2622
4472000Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxelHsu C.-H.; Chen M.-Y.; ANN-LII CHENG Anticancer Research64
4481999Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapyYeh K.-H.; Shun C.-T.; Chen C.-L.; Lin J.-T.; Lee W.-J.; Lee P.-H.; Chen Y.-C.; ANN-LII CHENG Hepato-Gastroenterology2324
4491999Quiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphomaYeh K.-H.; Lien H.-C.; Hsu S.-M.; ANN-LII CHENG American Journal of Hematology29
4501999High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinomaYang C.-H.; ANN-LII CHENG ; Yeh K.-H.; Yu C.-J.; Lin J.-F.; Yang P.-C.Cancer23
4511999Hypermethylation of the p16 gene in sporadic T3NOMO stage colorectal cancers: Association with DNA replication error and shorter survivalLiang J.-T.; Chang K.-J.; Chen J.-C.; Lee C.-C.; Cheng Y.-M.; Hsu H.-C.; Wu M.-S.; Wang S.-M.; Lin J.-T.; ANN-LII CHENG Oncology7469
4521999The significance of body weight change in non-Hodgkins lymphomaChin Y.H.; Liu J.M.; Tai J.J.; Chuang M.S.; Ho Y.L.; Chen Y.M.; Whang-Peng J.; ANN-LII CHENG Anticancer Research43
4531999Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracilHsu C.-H.; Yeh K.-H.; Lui L.T.; Lee Y.-C.; Bu C.-F.; Wang H.-P.; Lin J.-T.; ANN-LII CHENG Anticancer Research2926
4541998Gastric cancer associated with acute disseminated intravascular coagulation: Successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorinYeh K.-H.; ANN-LII CHENG British Journal of Haematology3934
4551998Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: A pilot study of the BOMES protocolANN-LII CHENG ; Yeh K.-H.; Uen W.-C.; Hung R.-L.; Liu M.-Y.; Wang C.-H.Cancer59
4561998Encephalopathy, lactic acidosis, hyperammonaemia and 5-fluorouracil toxicity (multiple letters) [1]Valik D.; Yeh K.-H.; ANN-LII CHENG British Journal of Cancer35
4571998High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancersYeh K.-H.; Lin M.-T.; Lin D.-T.; Tang J.-L.; Lui L.-T.; Lin J.-F.; Chang Y.-S.; ANN-LII CHENG ; Yu S.-C.; Chang K.-J.; Chen Y.-C.Breast Cancer Research and Treatment22
4581998Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19) - Possible clinical significance in advanced gastric cancerYeh K.-H.; Chen Y.-C.; Yeh S.-H.; Chen C.-P.; Lin J.-T.; ANN-LII CHENG Anticancer Research4643
4591998Research nurses for clinical trials of anti-cancer drugs: Developing a new subspecialty in TaiwanANN-LII CHENG ; Lai Y.-H.; Yu Y.-C.Drug Information Journal00
4601998Megestrol acetate antagonizes cisplatin cytotoxicityPu Y.-S.; ANN-LII CHENG ; Chen J.; Guan J.-Y.; Lu S.-H.; Lai M.-K.; Hsieh C.-Y.Anti-Cancer Drugs33
4611998Transactivation of the human MDR1 gene by hepatitis B virus X gene productDoong S.-L.; Lin M.-H.; Tsai M.-M.; Li T.-R.; Chuang S.-E.; ANN-LII CHENG Journal of Hepatology1211
4621998Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suraminHutson P.R.; Tutsch R.D.; Rago R.; Arzoomanian R.; Alberti D.; Pomplun M.; Church D.; Marnocha R.; ANN-LII CHENG ; Kehrli N.; Wilding G.Clinical Cancer Research99
4631998Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifenANN-LII CHENG ; Chuang S.-E.; Fine R.L.; Yeh K.-H.; Liao C.-M.; Lay J.-D.; Chen D.-S.Biochemical Pharmacology6965
4641998High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapyYeh K.-H.; Shun C.-T.; Chen C.-L.; Lin J.-T.; Lee W.-J.; Lee P.-H.; Chen Y.-C.; ANN-LII CHENG Cancer105
4651998Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancersYeh K.-H.; Chen C.-L.; Shun C.-T.; Lin J.-T.; Lee W.-J.; Lee P.-H.; Chen Y.-C.; ANN-LII CHENG Journal of Clinical Gastroenterology15
4661998Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancerANN-LII CHENG ; Yeh K.-H.; Lin J.-T.; Hsu C.; Liu M.-Y.Anticancer Research2320
4671998Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinomaANN-LII CHENG ; Yeh K.-H.; Fine R.L.; Chuang S.-E.; Yang C.-H.; Wang L.-H.; Chen D.-S.Hepato-Gastroenterology4133
4681998Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activityKuo M.-L.; Shen S.-C.; Yang C.-H.; Chuang S.-E.; ANN-LII CHENG ; Huang T.-S.Oncogene3935
4691997Tax of the human T-lymphotropic virus type I transactivates promoter of the MDR-1 geneChuang S.-E.; Doong S.-L.; Lin M.-T.; ANN-LII CHENG Biochemical and Biophysical Research Communications89
4701997Angioimmunoblastic lymphadenopathy with dysproteinemia - lack of a prognostic value of clear cell morphologyCh’ang H.-J.; Su I.J.; Chen C.L.; Zmija I.P.; Chen Y.C.; Wang C.H.; ANN-LII CHENG Oncology (Switzerland)77
4711997MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancerHsu C.; Yeh K.-H.; Hong R.-L.; Yang C.-H.; Lin M.-T.; Chen Y.-C.; ANN-LII CHENG Journal of the Formosan Medical Association43
4721997High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lungYeh K.-H.; ANN-LII CHENG Anticancer Research1411
4731997Weekly CAF chemotherapy for advanced breast cancer patientsHwang W.-S.; Hsiung C.A.; Ko W.-S.; lVang C.-C.; Chang J.-V.; Lai G.-M.; Hsieh R.-K.; Tsao C.-J.; Chen L.-T.; Law C.-K.; ANN-LII CHENG ; Fan S.F.; Tzeng C.-H.; Chiou T.-J.; Whang-Peng J.Oncology (Switzerland)11
4741997Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlationChou Y.-Y.; ANN-LII CHENG ; Hsu H.-C.Journal of Gastroenterology and Hepatology (Australia)4341
4751997High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy [2]Yeh K.H.; ANN-LII CHENG British Journal of Cancer113
4761997Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancersHsu C.-H.; Yeh K.-H.; Chen L.-T.; Liu J.M.; Jan C.-M.; Lin J.-T.; Chen Y.-C.; ANN-LII CHENG Oncology (Switzerland)6051
4771997Early gastric cancer as a possible cause of cauda equina syndrome and disseminated intravascular coagulationWei S.-C.; Wong J.-M.; Chen C.-L.; ANN-LII CHENG ; Wang C.-Y.; Wang T.-H.Digestive Endoscopy00
4781997Stability of curcumin in buffer solutions and characterization of its degradation productsWang Y.-J.; Pan M.-H.; ANN-LII CHENG ; Lin L.-I.; Ho Y.-S.; Hsieh C.-Y.; Lin J.-K.Journal of Pharmaceutical and Biomedical Analysis12871175
4791997Transforming growth factor β1 attenuates ceramide-induced CPP32/Yama activation and apoptosis in human leukaemic HL-60 cellsKuo M.-L.; Chen C.-W.; Jee S.-H.; Chuang S.-E.; ANN-LII CHENG Biochemical Journal1819
4801997Factors associated with the therapeutic efficacy of retinoic acids on malignant lymphomasANN-LII CHENG ; Chuang S.-E.; Su I.-J.Journal of the Formosan Medical Association109
4811997Infrequent hMSH2 mutations in sporadic gastric adenocarcinoma with microsatellite instabilityWu M.-S.; Sheu J.-C.; Shun C.-T.; Lee W.-J.; Wang J.-T.; Wang T.-H.; ANN-LII CHENG ; Lin J.-T.Cancer letters2827
4821997Thymic carcinoma with autoimmune syndrome: Successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorinHsu C.-H.; Yeh K.-H.; ANN-LII CHENG Anticancer Research1717
4831997Prognostic significance of immunophenotypes in adult lymphoblastic lymphomasYeh K.-H.; ANN-LII CHENG ; Su I.H.-J.; Lin M.-T.; Tien H.-F.; Shen M.-C.; Wang C.-H.; Chen Y.-C.Anticancer Research2014
4841997A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancersYeh K.-H.; ANN-LII CHENG ; Lin M.-T.; Hong R.-L.; Hsu C.-H.; Lin J.-F.; Chang K.-J.; Lee P.-H.; Chen Y.-C.Anticancer Research3127
4851996Polyprenoic acid in hepatocellular carcinomaYang C.-H.J.; ANN-LII CHENG New England Journal of Medicine00
4861996Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma [3]ANN-LII CHENG Blood7159
4871996Expression of mdr-1 gene in transitional cell carcinoma and its correlation with chemotherapy responsePu Y.-S.; Tsai T.-C.; ANN-LII CHENG ; Tsai C.-Y.; Tseng N.-F.; Su I.H.-J.; Hsieh C.-Y.; Lai M.-K.Journal of Urology2625
4881996Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: A potential use in intravesical chemotherapyPu Y.-S.; Hsieh T.-S.; ANN-LII CHENG ; Tseng N.-F.; Su I.-J.; Hsieh C.-Y.; Lai M.-K.; Tsai T.-C.British Journal of Urology2221
4891996Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinomaANN-LII CHENG ; Chen Y.-C.; Yeh K.-H.; Chuang S.-E.; Chen B.-R.; Chen D.-S.Cancer37
4901996Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13-cis retinoic acidChou W.-C.; Su I.-J.; Tien H.-F.; Liang D.-C.; Wang C.-H.; Chang Y.-C.; ANN-LII CHENG Cancer41
4911996Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue: Clinicopathologic analysis of 19 casesChiang I.-P.; Wang H.-H.; ANN-LII CHENG ; Lin J.-T.; Su I.-J.Journal of the Formosan Medical Association99
4921995Growth of E.coli at low temperature dramatically increases the transformation frequency by electroporationChuang S.-E.; ANN-LII CHENG ; Chao C.-C.Nucleic Acids Research2019
4931995Clinicopathologic characteristics of helicobacter pyloric seropositive gastric adenocarcinomasLee W.-J.; Lin J.-T.; Lee W.C.; Shun C.-T.; Hong R.-L.; ANN-LII CHENG ; Lee P.-H.; Wei T.-C.; Chen K.-M.Journal of Clinical Gastroenterology1313
4941995Hemophagocytic syndrome in epstein-Barr virus-associated t-lymphoproliferative disorders: Disease spectrum, pathogenesis, and managementSu I.-J.; Wang C.-H.; ANN-LII CHENG ; Chen R.-L.Leukemia and Lymphoma121100
4951995Single-step direct cloning of PCR productsChuang S.-E.; Wang K.-C.; ANN-LII CHENG Trends in Genetics42
4961995Primary T cell leptomeningeal lymphoma – Successful treatment with systemic chemotherapyYeh K.H.; ANN-LII CHENG ; Tien H.F.Oncology (Switzerland)139
4971995Tamoxifen Enhances the Chemosensitivity of Bladder Carcinoma CellsPu Y.-S.; Hsieh T.-S.; Tsai T.-C.; ANN-LII CHENG ; Hsieh C.-Y.; Su I.-J.; Lai M.-K.The Journal of Urology3430
4981994Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: A pilot studyYeh K.-H.; ANN-LII CHENG ; Chen Y.-C.; Chen B.-R.; Lee W.-J.; Lin J.-T.; Lee P.-H.; Chang K.-J.; Wang C.-H.; Wang T.-H.Journal of the Formosan Medical Association60
4991994Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acidYeh K.-H.; ANN-LII CHENG Journal of the Formosan Medical Association160
5001994Characteristic clinicopathologic features of adult B?cell lymphoblastic lymphoma with special emphasis on differential diagnosis with an atypical form probably of blastic lymphocytic lymphoma of intermediate differentiation originANN-LII CHENG ; Su I.?J.; Tien H.F.; Wang C.C.; Chen Y.C.; Wang C.H.Cancer17
5011994An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin [2]Yeh K.-H.; ANN-LII CHENG Journal of Clinical Oncology1816
5021994Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphomaYao M.; ANN-LII CHENG ; Su I.-J.; Lin M.-T.; Uen W.-C.; Tien H.-F.; Wang C.-H.; Chen Y.-C.British Journal of Haematology8166
5031994Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot studyANN-LII CHENG ; Su I.-J.; Chen C.-C.; Tien H.-F.; Lay J.-D.; Chen B.-R.; Pu Y.-S.; Hong R.-L.; Shen M.-C.; Wang C.-H.; Chen Y.-C.Journal of Clinical Oncology49
5041994Modulation of retinoic acid receptor alpha, growth factor and proto-oncogenes in retinoic acid-induced apoptosis of Ki-1 lymphoma cell lineSu I.-J.; Lay Z.-D.; ANN-LII CHENG ; Chang Y.-C.International Journal of Oncology6
5051993Retinoic acid?induced apoptosis and regression of a refractory Epstein?Barr virus?containing T cell lymphoma expressing multidrug?resistance phenotypesSu I.J.; ANN-LII CHENG ; Tsai T.F.; Lay J.D.British Journal of Haematology1615
5061993Cutaneous manifestations of Epstein-Barr virus—associated T-cell lymphomaSu I.-J.; Tsai T.-F.; ANN-LII CHENG ; Chen C.-C.Journal of the American Academy of Dermatology6457
5071993Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of epstein-barr virus, immunophenotypes, and other predisposing factorsANN-LII CHENG ; Su I.-J.; Chen Y.-C.; Lee T.-C.; Wang C.-H.Journal of Clinical Oncology7779
5081993Characteristic clinicopathologic features of epstein?barr virus—associated peripheral T?cell lymphomaANN-LII CHENG ; Su I.J.; Chen Y.C.; Uen W.C.; Wang C.H.Cancer82
5091993Epstein—barr virus?containing t?cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosisSu I.J.; Hsu Y.H.; Lin M.T.; ANN-LII CHENG ; Wang C.H.; Weiss L.M.Cancer79
5101992Present status of cancer treatment in TaiwanHow S.-W.; ANN-LII CHENG Japanese Journal of Cancer and Chemotherapy00
5111992Cutaneous angiocentric T-cell lymphoma associated with Epstein-Barr virusTsai T.-F.; Su I.-J.; Lu Y.-C.; ANN-LII CHENG ; Yeh H.-P.; Hsieh H.-C.; Tien H.-F.; Chen J.-S.; Uen W.-C.Journal of the American Academy of Dermatology5654
512199113?cis?retinoic acid induces cellular differentiation and durable remission in refractory cutaneous ki?1 lymphomaChow J.M.; ANN-LII CHENG ; Su I.J.; Wang C.H.Cancer22
5131991Disruption of Cellular Energy Balance by Suramin in Intact Human Prostatic Carcinoma Cells, a Likely Antiproliferative MechanismRago R.; Mitchen J.; ANN-LII CHENG ; Oberley T.; Wilding G.Cancer Research4142
5141991Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: A clinicopathologic and molecular analysisSu I.-J.; Hsieh H.-C.; Lin K.-H.; Uen W.-C.; Kao C.-L.; Chen C.-J.; ANN-LII CHENG ; Kadin M.E.; Chen J.-Y.Blood241269
5151991Menadione-induced DNA damage in a human tumor cell lineNgo E.O.; Sun T.-P.; Chang J.-Y.; Wang C.-C.; Chi K.-H.; ANN-LII CHENG ; Nutter L.M.Biochemical Pharmacology6574
5161991Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignanciesSu I.-J.; Chang I.-C.; ANN-LII CHENG Annals of Oncology1614
5171991Menadione: Spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell linesNutter L.M.; ANN-LII CHENG ; Hsiao-Ling H.; Ruey-Kun H.; Ngo E.O.; Tsang-Wu L.Biochemical Pharmacology113120
5181990Cutaneous manifestations of postthymic T cell malignancies: Description of five clinicopathologic subtypesSu I.-J.; Wu Y.-C.; Chen Y.-C.; Hsieh H.-C.; ANN-LII CHENG ; Wang C.-H.; Kadin M.E.Journal of the American Academy of Dermatology3935
5191989Adult non-Hodgkin's lymphoma in Taiwan area: A clinicopathologic study of 123 cases based on working formulation classificationANN-LII CHENG ; Chen Y.-C.; Su I.-J.; Wang C.-H.; Hsieh H.-C.; Chen C.-L.; Lai H.-S.; Liu T.-W.; Tien H.-F.; Shen M.-C.; Liu C.-H.Journal of the Formosan Medical Association120
5201989Bone marrow involvement in non-Hodgkin's lymphoma.Lai H.S.; Tien H.F.; Hsieh H.C.; Chen Y.C.; Su I.J.; Wang C.H.; Liu M.C.; ANN-LII CHENG ; Shen M.C.; Liu C.H.Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association110
5211989Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - Should peripheral T-cell lymphoma be considered separately?ANN-LII CHENG ; Chen Y.-C.; Wang C.-H.; Su I.-J.; Hsieh H.-C.; Chang J.-Y.; Hwang W.-S.; Su W.-C.; Liu T.-W.; Tien H.-F.; Tsai W.; Shen M.-C.; Liu C.-H.Journal of Clinical Oncology7065
5221988Characterization of the spectrum of postthymic T?cell malignancies in Taiwan a clinicopathologic study of HTLV?1?positive and HTLV?1?negative casesSu I.J.; Wang C.H.; ANN-LII CHENG ; Chen Y.C.; Hsieh H.C.; Tien H.F.; Huang S.S.; Hu C.Y.; Chen P.J.; Chen J.Y.; Hsu H.C.; Chuang S.M.; Shen M.C.; Kadin M.E.Cancer42
5231987Allogeneic bone marrow transplantation in the treatment of leukemia--a preliminary reportChen Y.C.; Wang C.H.; Lin D.T.; Lui P.T.; ANN-LII CHENG ; Liu T.W.; Tsay W.; Tien H.F.; Liu M.C.; Chuu W.M.Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association00
5241986Adult acute lymphoblastic leukemia--lineage specific classification of 30 cases.ANN-LII CHENG ; Chen Y.C.; Wang C.H.; Shen M.C.; Hsieh R.P.; Tien H.F.; Liu M.C.; Lai H.S.; Liu C.H.Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association00